



STIC Search Report

EIC 1700

STIC Database Tracking Number: 170002

TO: Kriellion Sanders
Location: REM 10D11
Art Unit : 1714
November 3, 2005

Case Serial Number: 10/690120

From: Les Henderson
Location: EIC 1700
REM 4B28 / 4A30
Phone: 571-272-2538

Leslie.henderson@uspto.gov

Search Notes

=> d his ful

(FILE 'HOME' ENTERED AT 08:31:24 ON 03 NOV 2005)

FILE 'HCAPLUS' ENTERED AT 08:31:33 ON 03 NOV 2005

E US200040087446/PN

E US20040087446/PN

L1 1 SEA ABB=ON PLU=ON US20040087446/PN
D ALL
SEL L1 RN

FILE 'REGISTRY' ENTERED AT 08:32:37 ON 03 NOV 2005

L2 30 SEA ABB=ON PLU=ON (104564-32-1/BI OR 106917-30-0/BI
OR 122586-52-1/BI OR 122586-95-2/BI OR 124172-53-8/BI
OR 147783-69-5/BI OR 152734-34-4/BI OR 164578-16-9/BI
OR 164648-93-5/BI OR 1753-47-5/BI OR 1843-05-6/BI OR
219991-91-0/BI OR 24937-78-8/BI OR 297748-93-7/BI OR
36768-62-4/BI OR 3864-99-1/BI OR 40075-75-0/BI OR
41556-26-7/BI OR 474043-37-3/BI OR 52829-07-9/BI OR
565450-39-7/BI OR 62782-03-0/BI OR 63843-89-0/BI OR
64022-57-7/BI OR 64022-61-3/BI OR 64337-97-9/BI OR
71029-16-8/BI OR 79720-19-7/BI OR 82537-67-5/BI OR
9002-88-4/BI)

D SCAN

E 152734-34-4/RN

L3 1 SEA ABB=ON PLU=ON 152734-34-4/RN
D SCAN

E 1753-47-5/RN

L4 1 SEA ABB=ON PLU=ON 1753-47-5/RN
D SCAN

L5 1 SEA ABB=ON PLU=ON 1753-47-5/CRN
D SCAN
D IDE

FILE 'LREGISTRY' ENTERED AT 08:52:19 ON 03 NOV 2005

L6 STR
L7 STR

FILE 'REGISTRY' ENTERED AT 08:59:34 ON 03 NOV 2005

L8 26 SEA SSS SAM L6 AND L7
D SCAN

FILE 'LREGISTRY' ENTERED AT 09:28:02 ON 03 NOV 2005

L9 STR L6
L10 STR L7
L11 STR L10
L12 STR L11

FILE 'REGISTRY' ENTERED AT 09:31:45 ON 03 NOV 2005

D QUE STAT L9

D QUE STAT L10

L13 50 SEA SSS SAM L9
D QUE STAT

L14 50 SEA SSS SAM L10

L15 50 SEA SSS SAM L11

L16 50 SEA SSS SAM L12

D QUE STAT L10

FILE 'LREGISTRY' ENTERED AT 09:34:53 ON 03 NOV 2005

FILE 'REGISTRY' ENTERED AT 09:39:43 ON 03 NOV 2005

D QUE STAT L13

L17 SCR 1838 AND 1992
L18 50 SEA SSS SAM L17 AND L9
L19 SCR 1838 AND 1992 AND 1104
L20 50 SEA SSS SAM L9 AND L19
L21 50 SEA SSS SAM L10 AND L9

FILE 'LREGISTRY' ENTERED AT 09:56:37 ON 03 NOV 2005
L22 STR L9

FILE 'REGISTRY' ENTERED AT 09:57:00 ON 03 NOV 2005
L23 50 SEA SSS SAM L22 AND L19
D QUE STAT
L24 139224 SEA SSS FUL L22 AND L19
SAV TEMP SAN120/A L24
L25 320563 SEA SSS FUL L10
SAV TEMP L25 SAN120A/A
D SAV
L26 2282 SEA ABB=ON PLU=ON L24 AND L25

FILE 'LREGISTRY' ENTERED AT 10:07:16 ON 03 NOV 2005
D QUE STAT L4
L27 STR 152734-34-4
L28 STR 1753-47-5

FILE 'REGISTRY' ENTERED AT 10:17:54 ON 03 NOV 2005
L29 0 SEA SUB=L25 SSS SAM L27
D QUE STAT
L30 7 SEA SUB=L25 SSS SAM L28
D QUE STAT
D SCAN

FILE 'LREGISTRY' ENTERED AT 10:32:08 ON 03 NOV 2005
L31 STR L27
L32 STR L28

FILE 'REGISTRY' ENTERED AT 10:40:22 ON 03 NOV 2005
L33 0 SEA SUB=L25 SSS SAM L31
D QUE STAT
L34 50 SEA SUB=L25 SSS SAM L32
D QUE STAT

FILE 'LREGISTRY' ENTERED AT 10:42:56 ON 03 NOV 2005
L35 STR L31
L36 STR L28

FILE 'REGISTRY' ENTERED AT 10:45:10 ON 03 NOV 2005
L37 0 SEA SUB=L25 SSS SAM L35
D QUE STAT
L38 19 SEA SUB=L25 SSS SAM L36
D QUE STAT
D QUE STAT L37
L39 8 SEA SUB=L25 SSS FUL L35
D SCAN
D QUE STAT L38
L40 210 SEA SUB=L25 SSS FUL L36
D QUE STAT L34
L41 1234 SEA SUB=L25 SSS FUL L32
SAV L39 SAN120B/A
SAV L40 SAN120C/A
SAV L41 SAN120D/A

FILE 'HCAPLUS' ENTERED AT 11:33:44 ON 03 NOV 2005

L42 29829 SEA ABB=ON PLU=ON L24

FILE 'REGISTRY' ENTERED AT 11:37:57 ON 03 NOV 2005

L43 320563 SEA ABB=ON PLU=ON L25 OR L25
D 160000 RN

L44 160000 SEA RAN=(196803-56-2,) ABB=ON PLU=ON L25 OR L25

L45 160563 SEA ABB=ON PLU=ON L43 NOT L44

FILE 'HCAPLUS' ENTERED AT 11:45:14 ON 03 NOV 2005

L46 13768 SEA ABB=ON PLU=ON L44

L47 242559 SEA ABB=ON PLU=ON L45

L48 1549 SEA ABB=ON PLU=ON L42 AND (L46 OR L47)
D L48 1-10 FHITSTR

L49 410 SEA ABB=ON PLU=ON L26
D 1-10 FHITSTR

L50 3 SEA ABB=ON PLU=ON L39
D SCAN

L51 140 SEA ABB=ON PLU=ON L40

L52 214 SEA ABB=ON PLU=ON L41

L53 74 SEA ABB=ON PLU=ON L52 NOT L51
D 1-5 FHITSTR

L54 725 SEA ABB=ON PLU=ON STERIC?(3A)HINDER?(3A)AMINE

L55 0 SEA ABB=ON PLU=ON L54 AND L51

L56 0 SEA ABB=ON PLU=ON L54 AND L52

L57 2 SEA ABB=ON PLU=ON L54 AND L48
D SCAN

L58 1 SEA ABB=ON PLU=ON L54 AND L49
D SCAN

L59 2 SEA ABB=ON PLU=ON L57 OR L58

L60 7614 SEA ABB=ON PLU=ON STERIC?(3A)HINDER?

L61 755 SEA ABB=ON PLU=ON L60(4A)AMINE

L62 1387 SEA ABB=ON PLU=ON L60 AND AMINE

L63 0 SEA ABB=ON PLU=ON L61 AND L51

L64 0 SEA ABB=ON PLU=ON L61 AND L52

L65 2 SEA ABB=ON PLU=ON L61 AND L48

L66 1 SEA ABB=ON PLU=ON L61 AND L49

L67 2 SEA ABB=ON PLU=ON L59 OR L65 OR L66

L68 0 SEA ABB=ON PLU=ON L62 AND L51

L69 0 SEA ABB=ON PLU=ON L62 AND L52

L70 2 SEA ABB=ON PLU=ON L62 AND L48

L71 1 SEA ABB=ON PLU=ON L62 AND L49

L72 2 SEA ABB=ON PLU=ON L67 OR L70 OR L71

L73 74458 SEA ABB=ON PLU=ON (UV OR ULTRAVIOLET OR ULTRA(A)VIOLE
T) (3A)ABSOR?
D 1-5 KWIC

L74 6 SEA ABB=ON PLU=ON L73 AND L51

L75 7 SEA ABB=ON PLU=ON L73 AND L52

L76 7 SEA ABB=ON PLU=ON L73 AND L48

L77 2 SEA ABB=ON PLU=ON L73 AND L49

L78 14 SEA ABB=ON PLU=ON (L74 OR L75 OR L76 OR L77)

L79 15 SEA ABB=ON PLU=ON L78 OR L72
D SCAN TI
D QUE STAT L42
D QUE STAT L46
D QUE STAT L48
D QUE STAT L50
D QUE STAT L79
D QUE STAT L52

L80 8 SEA ABB=ON PLU=ON L54 AND L42
D SCAN TI

L81 0 SEA ABB=ON PLU=ON L1 AND L80

L82 4 SEA ABB=ON PLU=ON (L46 OR L47) AND L54


```

      D SCAN TI
L83      41 SEA ABB=ON PLU=ON L60 AND L42
L84      59 SEA ABB=ON PLU=ON L60 AND (L46 OR L47)
L85      0 SEA ABB=ON PLU=ON L1 AND L83
L86      0 SEA ABB=ON PLU=ON L1 AND L84
L87      3 SEA ABB=ON PLU=ON L73 AND (L84 OR L85)
L88      166 SEA ABB=ON PLU=ON L73 AND L42
L89      1853 SEA ABB=ON PLU=ON L73 AND (L46 OR L47)
L90      1 SEA ABB=ON PLU=ON L88 AND L54
L91      1 SEA ABB=ON PLU=ON L89 AND L54
L92      3 SEA ABB=ON PLU=ON L88 AND L60
L93      3 SEA ABB=ON PLU=ON L89 AND L60
L94      21 SEA ABB=ON PLU=ON L79 OR L82 OR L87 OR (L90 OR L91
      OR L92 OR L93)
L95      4728 SEA ABB=ON PLU=ON HINDER? (3A)AMINE
L96      2 SEA ABB=ON PLU=ON L95 AND L48
      D SCAN
L97      0 SEA ABB=ON PLU=ON L95 AND L50
L98      0 SEA ABB=ON PLU=ON L95 AND L51
L99      0 SEA ABB=ON PLU=ON L95 AND L52
L100     38 SEA ABB=ON PLU=ON L95 AND L42
L101     2 SEA ABB=ON PLU=ON L95 AND (L46 OR L48)
L102     2 SEA ABB=ON PLU=ON L100 AND L101
      D SCAN
L103     1689 SEA ABB=ON PLU=ON L48 OR L50 OR L51
L104     2 SEA ABB=ON PLU=ON L103 AND L54
L105     2 SEA ABB=ON PLU=ON L103 AND L62
L106     2 SEA ABB=ON PLU=ON L103 AND L60
L107     13 SEA ABB=ON PLU=ON L103 AND L73
L108     2 SEA ABB=ON PLU=ON L103 AND L95
L109     1 SEA ABB=ON PLU=ON L103 AND L95 AND L73
L110     14 SEA ABB=ON PLU=ON (L104 OR L105 OR L106 OR L107 OR
      L108 OR L109)
L111     7 SEA ABB=ON PLU=ON L94 NOT L110
      D L111 1-7 HITSTR
L112     0 SEA ABB=ON PLU=ON L52 AND (L54 OR L61 OR L62 OR L95)

L113     7 SEA ABB=ON PLU=ON L52 AND L73
      D SCAN TI
L114     21 SEA ABB=ON PLU=ON (L104 OR L105 OR L106 OR L107 OR
      L108 OR L109 OR L110 OR L111 OR L112 OR L113)
L115     0 SEA ABB=ON PLU=ON L1 AND L114
L116     1 SEA ABB=ON PLU=ON L1 AND L50
L117     1 SEA ABB=ON PLU=ON L1 AND L51
L118     1 SEA ABB=ON PLU=ON L1 AND L52
L119     0 SEA ABB=ON PLU=ON L1 AND L48
L120     5824 SEA ABB=ON PLU=ON L24 (L) RACT/RL
L121     5166 SEA ABB=ON PLU=ON L44 (L) RACT/RL
L122     30833 SEA ABB=ON PLU=ON L45 (L) RACT/RL
L123     206 SEA ABB=ON PLU=ON L120 AND (L121 OR L122)
      D 1 HITSTR
L124     5419 SEA ABB=ON PLU=ON (STERIC? OR HINDER?) (3A)AMINE
L125     0 SEA ABB=ON PLU=ON L124 AND L123
L126     9406 SEA ABB=ON PLU=ON (STERIC? OR HINDER?) (L)AMINE
L127     0 SEA ABB=ON PLU=ON L123 AND L126
L128     2 SEA ABB=ON PLU=ON L48 AND L124

```

FILE 'REGISTRY' ENTERED AT 14:03:16 ON 03 NOV 2005

D QUE STAT L6

D QUE STAT L24

D QUE STAT L7

L129 50 SEA SUB=L24 SSS SAM L6

L130 39271 SEA SUB=L24 SSS FUL L6
D SAV
SAV L130 SAV120E/A

FILE 'HCAPLUS' ENTERED AT 14:06:59 ON 03 NOV 2005

L131 1905 SEA ABB=ON PLU=ON L130(L) RACT/RL
L132 94 SEA ABB=ON PLU=ON L131 AND (L121 OR L122)

FILE 'REGISTRY' ENTERED AT 14:08:32 ON 03 NOV 2005

D QUE STAT L7
D QUE STAT L24
D QUE STAT L25
D QUE STAT L25

L133 50 SEA SUB=L25 SSS SAM L7
L134 50778 SEA SUB=L25 SSS FUL L7
SAV L134 SAV120F/A

FILE 'HCAPLUS' ENTERED AT 14:11:39 ON 03 NOV 2005

L135 2884 SEA ABB=ON PLU=ON L134(L) RACT/RL
L136 17 SEA ABB=ON PLU=ON L131 AND L135
D SCAN
D SCAN TI

L137 77 SEA ABB=ON PLU=ON L132 NOT L136
L138 0 SEA ABB=ON PLU=ON L137 AND L126
L139 0 SEA ABB=ON PLU=ON L137 AND L73
D QUE STAT

L140 10621 SEA ABB=ON PLU=ON (FILM? OR COVER?) (3A) (GREENHOUS?
OR GREEN(A)HOUS? OR TUNNEL? OR NET# OR NETTING? OR
SCREEN? OR MESH? OR MULCH?)
L141 0 SEA ABB=ON PLU=ON L140 AND L137
L142 1 SEA ABB=ON PLU=ON L140 AND L52
D SCAN

L143 7 SEA ABB=ON PLU=ON L52 AND (FIBER? OR FIBR? OR
FILAMENT? OR THREAD? OR STRAND? OR RIBBON? OR FILIFORM?
)
D SCAN TI

L144 9217 SEA ABB=ON PLU=ON (FIBER? OR FIBR? OR FILAMENT? OR
THREAD? OR STRAND? OR RIBBON? OR FILIFORM?) (5A) (GREENHO
US? OR GREEN(A)HOUS? OR TUNNEL? OR NET# OR NETTING? OR
SCREEN? OR MESH? OR MULCH?)
L145 0 SEA ABB=ON PLU=ON L144 AND L52
L146 0 SEA ABB=ON PLU=ON L144 AND L137
L147 0 SEA ABB=ON PLU=ON L144 AND L132
L148 0 SEA ABB=ON PLU=ON L144 AND L135
L149 3 SEA ABB=ON PLU=ON L137 AND (FIBER? OR FIBR? OR
FILAMENT? OR THREAD? OR STRAND? OR RIBBON? OR FILIFORM?
)

L150 8 SEA ABB=ON PLU=ON L132 AND (FIBER? OR FIBR? OR
FILAMENT? OR THREAD? OR STRAND? OR RIBBON? OR FILIFORM?
)

L151 5 SEA ABB=ON PLU=ON L136 AND (FIBER? OR FIBR? OR
FILAMENT? OR THREAD? OR STRAND? OR RIBBON? OR FILIFORM?
)

L152 5 SEA ABB=ON PLU=ON L136 AND L151
L153 88 SEA ABB=ON PLU=ON L48 AND CONDENS?
L154 11 SEA ABB=ON PLU=ON L132 AND CONDENS?
L155 61 SEA ABB=ON PLU=ON L114 OR L128 OR L136 OR L142 OR
L143 OR (L149 OR L150 OR L151 OR L152) OR L154 OR L50

L156 55 SEA ABB=ON PLU=ON L155 AND ((L48 OR L49 OR L50 OR
L51 OR L52) OR L132 OR L136)

L157 6 SEA ABB=ON PLU=ON L155 NOT L156
D SCAN TI


```

      D SCAN
L158   55 SEA ABB=ON  PLU=ON  L155 AND ((L48 OR L49 OR L50 OR
      L51 OR L52) OR L136)
L159   52 SEA ABB=ON  PLU=ON  L158 NOT L50
L160   35 SEA ABB=ON  PLU=ON  L159 NOT L136
      D SCAN L160 TI
L161    2 SEA ABB=ON  PLU=ON  L3
L162   57 SEA ABB=ON  PLU=ON  L4
      D QUE STAT
L163   58 SEA ABB=ON  PLU=ON  L161 OR L162
L164    6 SEA ABB=ON  PLU=ON  L158 AND L163
L165    6 SEA ABB=ON  PLU=ON  L155 AND L163
L166  106 SEA ABB=ON  PLU=ON  L159 OR L163
L167  104 SEA ABB=ON  PLU=ON  L166 NOT L50
L168   87 SEA ABB=ON  PLU=ON  L167 NOT L136
L169   56 SEA ABB=ON  PLU=ON  L168 AND L163
L170   31 SEA ABB=ON  PLU=ON  L168 NOT L169
L171   62 SEA ABB=ON  PLU=ON  L51 AND L168
L172    6 SEA ABB=ON  PLU=ON  L171 NOT L163
L173   56 SEA ABB=ON  PLU=ON  L171 NOT L172
L174  107 S L166 OR L50 OR L136 OR L154 OR L163
L175    3 S L174 AND L50
L176  104 S L174 NOT L175
L177   11 S L154 AND L176
L178   93 S L176 NOT L177
L179   16 S L136 AND L178
L180   77 S L178 NOT L179
L181   56 S L180 AND L163
L182   21 S L180 NOT L181

```

=> => d que stat 124

L19 SCR 1838 AND 1992 AND 1104
L22 STR



VPA 9-4/3/2/1/6 U

NODE ATTRIBUTES:

NSPEC IS RC AT 7

NSPEC IS RC AT 9

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 8

STEREO ATTRIBUTES: NONE


L24 139224 SEA FILE=REGISTRY SSS FUL L22 AND L19

100.0% PROCESSED 980882 ITERATIONS

SEARCH TIME: 00.00.05

139224 ANSWERS

=> d que stat 125
L10 STR




NODE ATTRIBUTES:
CONNECT IS E1 RC AT 7
CONNECT IS E1 RC AT 9
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 8

STEREO ATTRIBUTES: NONE
L25 320563 SEA FILE=REGISTRY SSS FUL L10

100.0% PROCESSED 345428 ITERATIONS (1 INCOMPLETE) 320563 ANSWERS
SEARCH TIME: 00.00.04


=> d que stat 139
L10 STR



NODE ATTRIBUTES:
CONNECT IS E1 RC AT 7
CONNECT IS E1 RC AT 9
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 8

STEREO ATTRIBUTES: NONE
L25 320563 SEA FILE=REGISTRY SSS FUL L10
L35 STR



N @28

VPA 28-23/24/25/26/27 U

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 25

STEREO ATTRIBUTES: NONE

L39 8 SEA FILE=REGISTRY SUB=L25 SSS FUL L35


100.0% PROCESSED 179 ITERATIONS

SEARCH TIME: 00.00.01

8 ANSWERS

=> d que stat 140

L10 STR



NODE ATTRIBUTES:

CONNECT IS E1 RC AT 7

CONNECT IS E1 RC AT 9

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 8

STEREO ATTRIBUTES: NONE

L25 320563 SEA FILE=REGISTRY SSS FUL L10

L36 STR



VPA 5-15/16/17/18/19 U

NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE
 L40 210 SEA FILE=REGISTRY SUB=L25 SSS FUL L36

100.0% PROCESSED 3736 ITERATIONS
 SEARCH TIME: 00.00.01

210 ANSWERS


=> d que stat l41
 L10 STR



NODE ATTRIBUTES:
 CONNECT IS E1 RC AT 7
 CONNECT IS E1 RC AT 9
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 8

STEREO ATTRIBUTES: NONE
 L25 320563 SEA FILE=REGISTRY SSS FUL L10
 L32 STR



VPA 20-16/18/19/17/15 U
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE
 L41 1234 SEA FILE=REGISTRY SUB=L25 SSS FUL L32

100.0% PROCESSED 26275 ITERATIONS
 SEARCH TIME: 00.00.02

1234 ANSWERS


=> d que stat 1130
 L6 STR



VPA 9-4/3/2/1/6 U
 NODE ATTRIBUTES:
 CONNECT IS E1 RC AT 8
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 9

STEREO ATTRIBUTES: NONE
 L19 SCR 1838 AND 1992 AND 1104
 L22 STR



VPA 9-4/3/2/1/6 U

NODE ATTRIBUTES:

NSPEC IS RC AT 7

NSPEC IS RC AT 9

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 8

STEREO ATTRIBUTES: NONE

L24 139224 SEA FILE=REGISTRY SSS FUL L22 AND L19

L130 39271 SEA FILE=REGISTRY SUB=L24 SSS FUL L6


100.0% PROCESSED 84820 ITERATIONS

39271 ANSWERS

SEARCH TIME: 00.00.01

=> d que stat 1134

L7 STR



NODE ATTRIBUTES:

CONNECT IS E1 RC AT 7

CONNECT IS E1 RC AT 8

CONNECT IS E1 RC AT 9

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 9

STEREO ATTRIBUTES: NONE

L10 STR



NODE ATTRIBUTES:

CONNECT IS E1 RC AT 7
 CONNECT IS E1 RC AT 9
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 8

STEREO ATTRIBUTES: NONE

L25 320563 SEA FILE=REGISTRY SSS FUL L10
 L134 50778 SEA FILE=REGISTRY SUB=L25 SSS FUL L7

100.0% PROCESSED 54439 ITERATIONS
 SEARCH TIME: 00.00.02

50778 ANSWERS

=> d 1175 1-3 cbib abs hitstr hitind

L175 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN

2004:607981 Document No. 142:114001 6-Aminouracils as precursors for the syntheses of fused di- and tricyclic pyrimidines. Youssif, Shaker (Chemistry Department, Faculty of Science, Zagazig University, Zagazig, Egypt). Journal of Chemical Research (5), 341-343 (English) 2004. CODEN: JCROA4. OTHER SOURCES: CASREACT 142:114001. Publisher: Science Reviews.

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT
 *

AB Treatment of uracils I (R = benzyl, Me) with nucleophilic primary amines, followed by nitrosation, reduction, formylation and dehydrocyclization, led to xanthenes II (R = benzyl, Y = H; R = Me, Y = Ph). Reaction of uracil III with aromatic aldehydes gave dipyrimidopyridines IV (R1 = H, Cl, OH, NO2, OMe, R2 = H; R1 = OMe, R2 = OH); reaction of III with formalin and primary amines gave pyrimidopyrimidines V [R3 = (un)substituted Ph, cyclohexyl] via double Michael reactions.


IT 823221-54-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (fused pyrimidines via heterocyclization reactions of 6-aminouracils with amines and aldehydes)

RN 823221-54-1 HCAPLUS

CN Pyrido[2,3-d:6,5-d']dipyrimidine-2,4,6,8(1H,3H,7H,9H)-tetrone,

1,9-bis[(2-chlorophenyl)methyl]-5,10-dihydro-5-(4-nitrophenyl)-
(9CI) (CA INDEX NAME)



CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
IT 445482-00-8P 823221-49-4P 823221-51-8P 823221-52-9P
823221-53-0P 823221-54-1P 823221-55-2P 823221-56-3P
823221-57-4P 823221-58-5P 823221-59-6P 823221-60-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(fused pyrimidines via heterocyclization reactions of
6-aminouracils with amines and aldehydes)

L175 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN

2004:348022 Document No. 140:358239 Composition and process for
enhancing biomass production in greenhouses. Destro, Mara;
Bonora, Michela; Magnani, Galileo (Ciba Specialty Chemicals
Holding Inc., Switz.; Ciba Specialty Chemicals S.P.A.). Eur. Pat.
Appl. EP 1413599 A1 20040428, 59 pp. DESIGNATED STATES: R: AT,
BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE,
SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK.
(English). CODEN: EPXXDW. APPLICATION: EP 2003-405736 20031014.
PRIORITY: EP 2002-405904 20021022.


AB A thermoplastic polymer composition is useful in greenhouse films to
enhance plant growth or in general bio-mass production A photoactive
additive together with light stabilizers is added into the
greenhouse film. The condensation product of dialkylamino
benzaldehyde and barbituric acid together with light stabilizers
act as a plant growth enhancing additive in polymeric greenhouse
films.

IT 1753-47-5 152734-34-4


RL: MOA (Modifier or additive use); USES (Uses)
(additive package of photoactive composition and light stabilizers
for enhancing biomass production in greenhouses)

RN 1753-47-5 HCAPLUS

CN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-[[4-
(dimethylamino)phenyl]methylene]- (9CI) (CA INDEX NAME)



RN 152734-34-4 HCAPLUS
 CN Pyrido[2,3-d:6,5-d']dipyrimidine-2,4,6,8(1H,3H,7H,9H)-tetrone,
 5-[4-(dimethylamino)phenyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




IC ICM C08K005-3462
 ICS C08K005-3465; C08J005-18
 CC 37-6 (Plastics Manufacture and Processing)
 Section cross-reference(s): 38
 IT 1753-47-5 1843-05-6, Chimassorb 81 3864-99-1, Tinuvin
 327 36768-62-4, 2,2,6,6-Tetramethyl-4-aminopiperidine
 40075-75-0, 3-Octyl-7,7,9,9-tetramethyl-1,3,8-
 triazaspiro[4.5]decane-2,4-dione 41556-26-7,
 Bis(1,2,2,6,6-pentamethyl-4-piperidyl)sebacate 52829-07-9,
 Bis(2,2,6,6-tetramethyl-4-piperidyl)sebacate 62782-03-0,
 Bis(2,2,6,6-tetramethyl-4-piperidyl)succinate 63843-89-0,
 Bis(1,2,2,6,6-pentamethyl-4-piperidyl)butyl-3,5-di-tert-butyl-4-
 hydroxybenzylmalonate 64022-57-7 64022-61-3,
 Tetrakis(2,2,6,6-tetramethyl-4-piperidyl)-1,2,3,4-butane
 tetracarboxylate 64337-97-9, 2-Undecyl-7,7,9,9-tetramethyl-1-oxa-
 3,8-diaza-4-oxospiro[4.5]decane 71029-16-8, 1,1-(1,2-Ethanediy)-
 bis(3,3,5,5-tetramethylpiperazinone) 79720-19-7,
 3-Dodecyl-1-(2,2,6,6-tetramethyl-4-piperidyl)pyrrolidine-2,5-dione
 82537-67-5, 8-Acetyl-3-dodecyl-7,7,9,9-tetramethyl-1,3,8-
 triazaspiro[4.5]decane-2,4-dione 104564-32-1,
 4-Stearyloxy-2,2,6,6-tetramethylpiperidine 106917-30-0,
 3-Dodecyl-1-(1,2,2,6,6-pentamethyl-4-piperidyl)pyrrolidine-2,5-
 dione 122586-52-1, Bis(1-octyloxy-2,2,6,6-tetramethyl-4-
 piperidyl)sebacate 122586-95-2, Bis(1-octyloxy-2,2,6,6-
 tetramethylpiperidyl)succinate 124172-53-8 147783-69-5,
 1,1-Bis(1,2,2,6,6-pentamethyl-4-piperidyloxycarbonyl)-2-(4-
 methoxyphenyl)ethene 152734-34-4 164648-93-5
 219991-91-0, 4-Benzoyl-2,2,6,6-tetramethylpiperidine 297748-93-7
 474043-37-3 565450-39-7, Tinuvin NOR 371
 RL: MOA (Modifier or additive use); USES (Uses)
 (additive package of photoactive composition and light stabilizers
 for enhancing biomass production in greenhouses)

L175 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN

1994:106924 Document No. 120:106924 Synthesis and antileishmanial activity of 5,10-dihydropyrido[2,3-d:6,5-d']dipyrimidine-5-(substituted phenyl)-2,4,6,8-[1H,3H,7H,9H]-tetraones. Khajuria, R. K.; Sharma, S. R.; Jain, S. M.; Sharma, Shalini; Kapil, Aruna (Dep. Chem., Reg. Res. Lab., Jammu, 180 001, India). Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 32B(9), 981-3 (English) 1993. CODEN: IJSBDB. ISSN: 0376-4699.

GI




AB Title compds. I [R = 3-HOC₆H₄; 4-MeOC₆H₄; 4-Me₂NC₆H₄; 2-, 3-, or 4-O₂NC₆H₄; 3,5-MeO(I)C₆H₃; 2,3-, 2,4-, 2,5-, or 3,4-(HO)₂C₆H₃; 3,4- or 3,6-HO(O₂N)C₆H₃; 3,4- or 3,2-MeO(HO)C₆H₃; 3,4,5-MeO(HO)(O₂N)C₆H₂; 3,4-methylenedioxyphenyl] were prepared by condensation of substituted benzaldehydes RCHO with barbituric acid in the presence of ammonium hydroxide in EtOH. The structures I were established by IR, ¹H- and ¹³C-NMR, and mass spectral data. I were tested for antileishmanial activity.

IT 152734-21-9P 152734-22-0P 152734-23-1P
152734-24-2P 152734-30-0P 152734-31-1P
152734-34-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antileishmanial activity of)


RN 152734-21-9 HCAPLUS

CN Pyrido[2,3-d:6,5-d']dipyrimidine-2,4,6,8(1H,3H,7H,9H)-tetrone,
5,10-dihydro-5-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 152734-22-0 HCAPLUS


CN Pyrido[2,3-d:6,5-d']dipyrimidine-2,4,6,8(1H,3H,7H,9H)-tetrone,
5,10-dihydro-5-(2-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 152734-23-1 HCAPLUS
CN Pyrido[2,3-d:6,5-d']dipyrimidine-2,4,6,8(1H,3H,7H,9H)-tetrone,
5,10-dihydro-5-(4-hydroxy-3-methoxy-5-nitrophenyl)- (9CI) (CA
INDEX NAME)




RN 152734-24-2 HCAPLUS
CN Pyrido[2,3-d:6,5-d']dipyrimidine-2,4,6,8(1H,3H,7H,9H)-tetrone,
5,10-dihydro-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 152734-30-0 HCAPLUS
CN Pyrido[2,3-d:6,5-d']dipyrimidine-2,4,6,8(1H,3H,7H,9H)-tetrone,
5,10-dihydro-5-(3-hydroxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 152734-31-1 HCAPLUS

CN Pyrido[2,3-d:6,5-d']dipyrimidine-2,4,6,8(1H,3H,7H,9H)-tetrone,
5,10-dihydro-5-(5-hydroxy-2-nitrophenyl)- (9CI) (CA INDEX NAME)

RN 152734-34-4 HCAPLUS

CN Pyrido[2,3-d:6,5-d']dipyrimidine-2,4,6,8(1H,3H,7H,9H)-tetrone,
5-[4-(dimethylamino)phenyl]-5,10-dihydro- (9CI) (CA INDEX NAME)CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 10


IT 152734-21-9P 152734-22-0P 152734-23-1P
 152734-24-2P 152734-25-3P 152734-26-4P 152734-27-5P
 152734-28-6P 152734-29-7P 152734-30-0P
 152734-31-1P 152734-32-2P 152734-33-3P
 152734-34-4P 152734-35-5P 152734-36-6P 152734-37-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and antileishmanial activity of)

=> d 1177 1-11 cbib abs hitstr hitind

L177 ANSWER 1 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN

2004:408271 Document No. 140:423521 Preparation of xanthines as inhibitors of dipeptidyl peptidase IV (DPP-IV). Himmelsbach, Frank; Langkopf, Elke; Eckhardt, Matthias; Maier, Roland; Mark, Michael; Tadayyon, Mohammad; Lotz, Ralf (Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G., Germany). Ger. Offen. DE 10251927 A1 20040519, 39 pp. (German). CODEN: GWXXBX. APPLICATION: DE 2002-10251927 20021108.

GI



AB Title compds. [I; R1 = (condensed heterocyclcyl- substituted) C1-3 alkyl, etc.; R2 = H, alkyl, alkenyl, alkynyl, cycloalkyl, etc.; R3 = (substituted) alkyl, aryl, alkenyl, alkynyl, etc.; R4 = (substituted) azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, hexahydroazepin-1-yl, etc.] and tautomerics, stereoisomerics, mixts., prodrug, and salts thereof, were prepared Thus, 1-[(1-methyl-2,2-dioxo-1H-benzo[c][1,2]thiazin-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert-butyloxycarbonylamino)piperidin-1-yl]xanthine (preparation given) in CH2Cl2 was treated with isopropanolic HCl followed by stirring for 3 h at room temperature to give 77% 1-[(1-methyl-2,2-dioxo-1H-benzo[c][1,2]thiazin-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-aminopiperidin-1-yl)xanthine. The latter inhibited DPP-IV with IC50 = 13 nM.

IT 668271-72-5P 690996-68-0P 690996-69-1P
690996-70-4P 690996-71-5P 690996-72-6P
690996-73-7P 690996-74-8P 690996-75-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of xanthines as inhibitors of dipeptidyl peptidase IV (DPP-IV))


RN 668271-72-5 HCAPLUS

CN 1H-Purine-2,6-dione, 8-(3-amino-1-piperidinyl)-7-(2-butyryl)-3,7-dihydro-3-methyl-1-[(1,2,3,4-tetrahydro-6-phenanthridinyl)methyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 668271-71-4


CMF C29 H33 N7 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 690996-68-0 HCAPLUS

CN 1H-Purine-2,6-dione, 8-(3-amino-1-piperidinyl)-3,7-dihydro-3-methyl-7-(3-methyl-2-butenyl)-1-[(1-methyl-2,2-dioxido-1H-2,1-benzothiazin-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 690996-69-1 HCAPLUS


CN 3-Isoquinolinecarboxylic acid, 1-[[8-(3-amino-1-piperidinyl)-7-(2-butenyl)-2,3,6,7-tetrahydro-3-methyl-2,6-dioxo-1H-purin-1-yl]methyl]-3,4-dihydro-3-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 690996-70-4 HCAPLUS


CN 1H-Purine-2,6-dione, 8-[(3R)-3-amino-1-piperidinyl]-7-(2E)-2-butenyl-1-[(2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-5-yl)methyl]-3,7-dihydro-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 690996-71-5 HCAPLUS

CN 1H-Purine-2,6-dione, 8-(3-amino-1-piperidinyl)-7-(2-butynyl)-3,7-dihydro-3-methyl-1-(6-phenanthridinylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl


RN 690996-72-6 HCAPLUS
 CN 1H-Purine-2,6-dione, 8-(3-amino-1-piperidinyl)-7-(2-butynyl)-1-(11H-dibenz[b,e]azepin-6-ylmethyl)-3,7-dihydro-3-methyl- (9CI)
 (CA INDEX NAME)



RN 690996-73-7 HCAPLUS
 CN 1H-Purine-2,6-dione, 8-(3-amino-1-piperidinyl)-7-(2-butynyl)-1-(dibenz[b,f][1,4]oxazepin-11-ylmethyl)-3,7-dihydro-3-methyl- (9CI)
 (CA INDEX NAME)




RN 690996-74-8 HCAPLUS
 CN 1H-Purine-2,6-dione, 8-(3-amino-1-piperidinyl)-7-(2-butynyl)-1-[(2,3-dihydro-1,4-benzoxazepin-5-yl)methyl]-3,7-dihydro-3-methyl- (9CI) (CA INDEX NAME)



RN 690996-75-9 HCAPLUS
 CN 1H-Purine-2,6-dione, 8-(3-amino-1-piperidinyl)-1-[(2,3-dihydro-3-oxo-1H-isindol-1-ylidene)methyl]-3,7-dihydro-3-methyl-7-(3-methyl-

2-butenyl)- (9CI) (CA INDEX NAME)




IT 93703-24-3

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of xanthines as inhibitors of dipeptidyl peptidase IV (DPP-IV))

RN 93703-24-3 HCAPLUS

CN 1H-Purine-2,6-dione, 8-bromo-3,7-dihydro-3-methyl- (9CI) (CA INDEX NAME)



IT 313273-69-7P 454709-36-5P 666816-89-3P
 666816-95-1P 666816-98-4P 666816-99-5P
 668272-43-3P 668272-54-6P 668272-95-5P
 668273-16-3P 668273-53-8P 668274-80-4P
 668274-97-3P 668275-59-0P 690996-52-2P
 690996-53-3P 690996-55-5P 690996-56-6P
 690996-57-7P 690996-63-5P 690996-64-6P
 690996-65-7P 690996-66-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP

(Preparation); RACT (Reactant or reagent)

(preparation of xanthines as inhibitors of dipeptidyl peptidase IV (DPP-IV))

RN 313273-69-7 HCAPLUS


CN 1H-Purine-2,6-dione, 8-bromo-3,7-dihydro-3-methyl-7-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)



RN 454709-36-5 HCAPLUS

CN Carbamic acid, [1-[2,3,6,7-tetrahydro-3-methyl-7-(3-methyl-2-butenyl)-2,6-dioxo-1H-purin-8-yl]-3-piperidinyl]-,

1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 666816-89-3 HCAPLUS

CN Carbamic acid, [(3R)-1-[7-(2E)-2-butenyl-2,3,6,7-tetrahydro-3-methyl-1-[2-(2-nitrophenyl)-2-oxoethyl]-2,6-dioxo-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 666816-95-1 HCAPLUS


CN 1H-Purine-2,6-dione, 8-bromo-7-(2E)-2-butenyl-3,7-dihydro-3-methyl-1-[2-(2-nitrophenyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 666816-98-4 HCAPLUS


CN 1H-Purine-2,6-dione, 8-bromo-7-(2-butynyl)-3,7-dihydro-3-methyl- (9CI) (CA INDEX NAME)



RN 666816-99-5 HCAPLUS


CN 1H-Purine-2,6-dione, 8-bromo-7-(2E)-2-butenyl-3,7-dihydro-3-methyl-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 668272-43-3 HCAPLUS

CN Carbamic acid, [1-[7-(2-butynyl)-2,3,6,7-tetrahydro-3-methyl-2,6-dioxo-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester
(9CI) (CA INDEX NAME)




RN 668272-54-6 HCAPLUS

CN Carbamic acid, [1-[7-(2-butynyl)-2,3,6,7-tetrahydro-1-[2-(2-hydroxyphenyl)-2-oxoethyl]-3-methyl-2,6-dioxo-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 668272-95-5 HCAPLUS

CN 1H-Purine-2,6-dione, 8-bromo-7-(2-butynyl)-3,7-dihydro-1-[2-(2-hydroxyphenyl)-2-oxoethyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 668273-16-3 HCAPLUS

CN Benzoic acid, 2-[[8-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-piperidinyl]-2,3,6,7-tetrahydro-3-methyl-7-(3-methyl-2-butenyl)-2,6-dioxo-1H-purin-1-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 668273-53-8 HCAPLUS

CN 1H-Purine-2,6-dione, 8-bromo-7-(2-butynyl)-3,7-dihydro-1-[2-(2-methoxyphenyl)-2-oxoethyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 668274-80-4 HCAPLUS

CN Carbamic acid, [1-[7-(2-butynyl)-2,3,6,7-tetrahydro-3-methyl-2,6-dioxo-1-[(1,2,3,4-tetrahydro-6-phenanthridinyl)methyl]-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 668274-97-3 HCAPLUS

CN Carbamic acid, [(3R)-1-[1-[2-(2-aminophenyl)-2-oxoethyl]-7-(2E)-2-butenyl-2,3,6,7-tetrahydro-3-methyl-2,6-dioxo-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.




RN 668275-59-0 HCAPLUS

CN Benzoic acid, 2-[[8-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-piperidinyl]-2,3,6,7-tetrahydro-3-methyl-7-(3-methyl-2-butenyl)-2,6-dioxo-1H-purin-1-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 690996-52-2 HCAPLUS

CN Carbamic acid, [1-[2,3,6,7-tetrahydro-3-methyl-7-(3-methyl-2-butenyl)-1-[(1-methyl-2,2-dioxido-1H-2,1-benzothiazin-4-yl)methyl]-2,6-dioxo-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 690996-53-3 HCAPLUS

CN 3-Isoquinolinecarboxylic acid, 1-[[7-(2-butynyl)-8-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-piperidinyl]-2,3,6,7-tetrahydro-3-methyl-2,6-dioxo-1H-purin-1-yl]methyl]-3,4-dihydro-3-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 690996-55-5 HCAPLUS

CN Carbamic acid, [1-[7-(2-butynyl)-2,3,6,7-tetrahydro-3-methyl-2,6-dioxo-1-(6-phenanthridinylmethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 690996-56-6 HCAPLUS

CN Carbamic acid, [1-[7-(2-butynyl)-1-(11H-dibenz[b,e]azepin-6-ylmethyl)-2,3,6,7-tetrahydro-3-methyl-2,6-dioxo-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 690996-57-7 HCAPLUS

CN Carbamic acid, [1-[7-(2-butynyl)-1-(dibenz[b,f][1,4]oxazepin-11-ylmethyl)-2,3,6,7-tetrahydro-3-methyl-2,6-dioxo-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 690996-63-5 HCAPLUS


CN Carbamic acid, [1-[7-(2-butynyl)-1-[2-[2-[2-[(1,1-dimethylethoxy)carbonyl]amino]ethoxy]phenyl]-2-oxoethyl]-2,3,6,7-tetrahydro-3-methyl-2,6-dioxo-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 690996-64-6 HCAPLUS

CN Carbamic acid, [1-[1-[(2,3-dihydro-1-hydroxy-3-oxo-1H-isoindol-1-yl)methyl]-2,3,6,7-tetrahydro-3-methyl-7-(3-methyl-2-butenyl)-2,6-dioxo-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester


(9CI) (CA INDEX NAME)



RN 690996-65-7 HCAPLUS

CN Carbamic acid, [(3R)-1-[7-(2E)-2-butenyl-1-[(2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-5-yl)methyl]-2,3,6,7-tetrahydro-3-methyl-2,6-dioxo-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester
(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 690996-66-8 HCAPLUS

CN Carbamic acid, [(3R)-1-[7-(2E)-2-butenyl-1-[2-[2-[(chloroacetyl)amino]phenyl]-2-oxoethyl]-2,3,6,7-tetrahydro-3-methyl-2,6-dioxo-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IC ICM C07D473-02
 CC 26-9 (Biomolecules and Their Synthetic Analogs)
 Section cross-reference(s): 1, 63
 IT 668271-72-5P 690996-68-0P 690996-69-1P
 690996-70-4P 690996-71-5P 690996-72-6P
 690996-73-7P 690996-74-8P 690996-75-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
 THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)
 (preparation of xanthines as inhibitors of dipeptidyl peptidase IV
 (DPP-IV))
 IT 870-63-3, 3,3-Dimethylallyl bromide 7117-09-1 39684-80-5
 93703-24-3 127525-80-8 172603-05-3 690996-62-4
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of xanthines as inhibitors of dipeptidyl peptidase IV
 (DPP-IV))
 IT 313273-69-7P 454709-36-5P 666816-89-3P
 666816-95-1P 666816-98-4P 666816-99-5P
 668272-43-3P 668272-54-6P 668272-95-5P
 668273-16-3P 668273-53-8P 668274-80-4P
 668274-97-3P 668275-49-8P 668275-59-0P
 668276-51-5P 690996-52-2P 690996-53-3P
 690996-55-5P 690996-56-6P 690996-57-7P
 690996-58-8P 690996-61-3P 690996-63-5P
 690996-64-6P 690996-65-7P 690996-66-8P
 690996-67-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP
 (Preparation); RACT (Reactant or reagent)
 (preparation of xanthines as inhibitors of dipeptidyl peptidase IV
 (DPP-IV))

L177 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN
 2003:758931 Document No. 139:364813 Synthesis and Pharmacological
 Evaluation of 1-Oxo-2-(3-piperidyl)-1,2,3,4-
 tetrahydroisoquinolines and Related Analogues as a New Class of
 Specific Bradycardic Agents Possessing If Channel Inhibitory
 Activity. Kubota, Hideki; Kakefuda, Akio; Watanabe, Toshihiro;
 Ishii, Noe; Wada, Koichi; Masuda, Noriyuki; Sakamoto, Shuichi;
 Tsukamoto, Shin-Ichi (Institute for Drug Discovery Research,
 Yamanouchi Pharmaceutical Co. Ltd., Tsukuba, Ibaraki, 305-8585,
 Japan). Journal of Medicinal Chemistry, 46(22), 4728-4740
 (English) 2003. CODEN: JMCMAR. ISSN: 0022-2623. OTHER SOURCES:
 CASREACT 139:364813. Publisher: American Chemical Society.
 AB A series of 1-oxo-2-(3-piperidyl)-1,2,3,4-tetrahydroisoquinolines

and related analogs were prepared and evaluated for their bradycardic activities in isolated right atrium and in anesthetized rats. (\pm)-6,7-Dimethoxy-2-{1-[3-(3,4-methylenedioxyphenoxy)propyl]-3-piperidyl}-1,2,3,4-tetrahydroisoquinoline was chosen as a lead, and structural modifications were performed on the tetrahydroisoquinoline ring and the terminal aromatic ring. The modifications on the tetrahydroisoquinoline ring revealed that the 1-oxo-1,2,3,4-tetrahydroisoquinoline ring system was optimum structure for both in vitro potency and in vivo efficacy. Furthermore, methoxy, ethoxy, and methoxycarbonyl groups were identified as preferable substituents on the terminal aromatic ring. One of the 1-oxo-1,2,3,4-tetrahydroisoquinoline derivs., was further evaluated for its bradycardic activity and inhibitory activity against If currents. This compound demonstrated potent bradycardic activity in rats with minimal influence on blood pressure after oral administration. The compound also showed inhibition of If currents ($IC_{50} = 0.32 \mu M$) in guinea pig pacemaker cells.

IT 619329-94-1P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation);

RACT (Reactant or reagent)

(coupling reaction of; preparation of oxo(piperidyl)tetrahydroisoquinolines and related analogs as class of specific bradycardic agents possessing If channel inhibitory activity)

RN 619329-94-1 HCAPLUS

CN 2,4(1H,3H)-Quinazolinedione, 6,7-dimethoxy-3-(3-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


IT 619329-93-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(cyclization of; preparation of oxo(piperidyl)tetrahydroisoquinolines and related analogs as class of specific bradycardic agents possessing If channel inhibitory activity)

RN 619329-93-0 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[2-[(ethoxycarbonyl)amino]-4,5-dimethoxybenzoyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 619329-95-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
 BIOL (Biological study); PREP (Preparation)
 (preparation of oxo(piperidyl)tetrahydroisoquinolines and related
 analogs as class of specific bradycardic agents possessing If
 channel inhibitory activity)

RN 619329-95-2 HCAPLUS

CN 2,4(1H,3H)-Quinazolin-6-one, 3-[1-[3-(1,3-benzodioxol-5-
 yloxy)propyl]-3-piperidinyl]-6,7-dimethoxy-, monohydrochloride
 (9CI) (CA INDEX NAME)



● HCl

CC 27-17 (Heterocyclic Compounds (One Hetero Atom))

Section cross-reference(s): 1

IT 120-20-7, 3,4-Dimethoxyphenethylamine 66802-60-6

RL: RCT (Reactant); RACT (Reactant or reagent)
 (condensation of; preparation of
 oxo(piperidyl)tetrahydroisoquinolines and related analogs as
 class of specific bradycardic agents possessing If channel
 inhibitory activity)

IT 619329-94-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
 preparation); BIOL (Biological study); PREP (Preparation);
 RACT (Reactant or reagent)

(coupling reaction of; preparation of oxo(piperidyl)tetrahydroisoqui-
 nolines and related analogs as class of specific bradycardic
 agents possessing If channel inhibitory activity)

IT 204979-28-2P 619329-93-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP
 (Preparation); RACT (Reactant or reagent)

(cyclization of; preparation of oxo(piperidyl)tetrahydroisoquinoline
 s and related analogs as class of specific bradycardic agents
 possessing If channel inhibitory activity)

IT 204979-57-7P 204979-61-3P 204979-86-2P 204979-89-5P

204979-90-8P 204979-91-9P 204979-94-2P 204979-95-3P

204980-10-9P 204980-11-0P 204980-12-1P 204980-13-2P

204980-14-3P 204980-15-4P 204980-16-5P 204980-17-6P
 619329-69-0P 619329-70-3P 619329-71-4P 619329-74-7P
 619329-78-1P 619329-81-6P 619329-82-7P 619329-83-8P
 619329-86-1P 619329-89-4P 619329-90-7P 619329-92-9P
 619329-95-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);



BIOL (Biological study); PREP (Preparation)

(preparation of oxo(piperidyl)tetrahydroisoquinolines and related
 analogs as class of specific bradycardic agents possessing If
 channel inhibitory activity)

L177 ANSWER 3 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN

1998:394328 Document No. 129:67773 Preparation of benzamide
 derivatives having a vasopressin antagonistic activity. Setoi,
 Hiroyuki; Ohkawa, Takehiko; Zenkoh, Tatsuya; Sawada, Hitoshi;
 Sawada, Yuki; Oku, Teruo (Fujisawa Pharmaceutical Co., Ltd.,
 Japan). PCT Int. Appl. WO 9824771 A1 19980611, 332 pp.
 DESIGNATED STATES: W: AU, CA, CN, HU, IL, JP, KR, MX, US, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, CH, DE, DK, ES, FI, FR,
 GB, GR, IE, IT, LU, MC, NL, PT, SE. (English). CODEN: PIXXD2.
 APPLICATION: WO 1997-JP4192 19971118. PRIORITY: AU 1996-3953
 19961202.

GI



AB The title compds. [I; R1 = (un)substituted aryl,
 cyclo(lower)alkyl, heterocyclyl; R2 = H, lower alkyl, etc.; R3 =
 H, halo, OH, etc.; A = a single bond, O, NH; E = lower alkylene,
 lower alkenylene, etc.; X = CH:CH, CH:N, S; Y = (un)substituted
 aryl, condensed heterocyclyl, etc.] and their
 pharmaceutically acceptable salts, useful in treatment and/or
 prevention of hypertension, heart failure, renal insufficiency,
 edema, ascites, vasopressin parasecretion syndrome,
 hepatocirrhosis, hyponatremia, hypokalemia, diabetic, circulation

disorder, cerebrovascular disease, Meniere's disease or motion sickness, were prepared. Thus, the title compound II showed IC₅₀ of 1.5 nM against vasopressin 1 receptor binding.

IT 208769-10-2P 208769-15-7P 208770-34-7P

208771-25-9P 208771-88-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation);


USES (Uses)

(preparation of benzamide derivs. having a vasopressin antagonistic activity)


RN 208769-10-2 HCAPLUS

CN 8-Quinazolinecarboxamide, 1,2,3,4-tetrahydro-N-[2-methoxy-4-[[methyl[4-methyl-2-[[6-(4-methyl-1-piperazinyl)-6-oxohexyl]oxy]phenyl]amino]carbonyl]phenyl]-2,4-dioxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 208769-15-7 HCAPLUS


CN 1H-Benzimidazole-4-carboxamide, 2-[[4-(dimethylamino)-1-piperidinyl]methyl]-N-[2-methoxy-4-[[methyl[4-methyl-2-[[6-(4-methyl-1-piperazinyl)-6-oxohexyl]oxy]phenyl]amino]carbonyl]phenyl]-

(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 208770-34-7 HCAPLUS
 CN 1H-Benzimidazole-4-carboxamide, 2-[4-(dimethylamino)-1-piperidinyl]-N-[2-methoxy-4-[[methyl[4-methyl-2-[[6-(4-methyl-1-piperazinyl)-6-oxohexyl]oxy]phenyl]amino]carbonyl]phenyl]- (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 208771-25-9 HCAPLUS

CN 1H-Benzimidazole-4-carboxamide, 2-[4-(dimethylamino)-1-piperidinyl]-N-[2-methoxy-4-[[methyl[4-methyl-2-[[6-(4-methyl-1-piperazinyl)-6-oxohexyl]oxy]phenyl]amino]carbonyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● 2 HCl

RN 208771-88-4 HCAPLUS
 CN 1H-Benzimidazole-4-carboxamide, 2-[[[4-(dimethylamino)-1-piperidinyl]methyl]-N-[2-methoxy-4-[[methyl[4-methyl-2-[[6-(4-methyl-1-piperazinyl)-6-oxohexyl]oxy]phenyl]amino]carbonyl]phenyl]-, trihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



●3 HCl


IT 67449-23-4

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of benzamide derivs. having a vasopressin antagonistic activity)

RN 67449-23-4 HCAPLUS

CN 2,4(1H,3H)-Quinazolinedione, 8-methyl- (9CI) (CA INDEX NAME)




IT 90418-81-8P 208772-31-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP
(Preparation); RACT (Reactant or reagent)
(preparation of benzamide derivs. having a vasopressin antagonistic
activity)


RN 90418-81-8 HCAPLUS

CN 8-Quinazolinecarboxylic acid, 1,2,3,4-tetrahydro-2,4-dioxo- (9CI)
(CA INDEX NAME)



RN 208772-31-0 HCAPLUS

CN Benzamide, N-[1-(hydroxymethyl)cyclopentyl]-2-nitro- (9CI) (CA
INDEX NAME)



IC ICM C07D235-08

ICS A61K031-415; A61K031-40; C07D235-14; C07D235-30; C07D209-08;
C07D209-42; C07D235-12; C07D235-24; C07D235-06; C07D235-10;
C07D235-26; C07D209-12; C07D401-04; C07D401-06

CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

IT	208767-69-5P	208767-72-0P	208767-75-3P	208767-77-5P
	208767-79-7P	208767-81-1P	208767-86-6P	208767-87-7P
	208767-88-8P	208767-89-9P	208767-90-2P	208767-91-3P
	208767-93-5P	208767-95-7P	208767-96-8P	208767-98-0P
	208767-99-1P	208768-00-7P	208768-02-9P	208768-04-1P
	208768-06-3P	208768-08-5P	208768-10-9P	208768-12-1P
	208768-13-2P	208768-15-4P	208768-16-5P	208768-17-6P
	208768-18-7P	208768-19-8P	208768-21-2P	208768-23-4P
	208768-24-5P	208768-25-6P	208768-26-7P	208768-28-9P
	208768-29-0P	208768-30-3P	208768-31-4P	208768-32-5P
	208768-33-6P	208768-34-7P	208768-35-8P	208768-37-0P
	208768-38-1P	208768-39-2P	208768-40-5P	208768-41-6P
	208768-42-7P	208768-43-8P	208768-44-9P	208768-45-0P
	208768-46-1P	208768-47-2P	208768-48-3P	208768-49-4P
	208768-50-7P	208768-51-8P	208768-52-9P	208768-53-0P
	208768-54-1P	208768-55-2P	208768-56-3P	208768-57-4P
	208768-58-5P	208768-59-6P	208768-60-9P	208768-61-0P
	208768-62-1P	208768-63-2P	208768-65-4P	208768-66-5P
	208768-67-6P	208768-68-7P	208768-69-8P	208768-70-1P
	208768-71-2P	208768-74-5P	208768-76-7P	208768-77-8P
	208768-78-9P	208768-79-0P	208768-80-3P	208768-81-4P
	208768-82-5P	208768-83-6P	208768-84-7P	208768-86-9P
	208768-89-2P	208768-90-5P	208768-91-6P	208768-92-7P
	208768-93-8P	208768-95-0P	208768-97-2P	208768-98-3P

208768-99-4P	208769-00-0P	208769-01-1P	208769-02-2P
208769-03-3P	208769-05-5P	208769-06-6P	208769-07-7P
208769-08-8P	208769-09-9P	208769-10-2P	208769-11-3P
208769-12-4P	208769-13-5P	208769-14-6P	208769-15-7P
208769-16-8P	208769-17-9P	208769-18-0P	208769-19-1P
208769-20-4P	208769-21-5P	208769-22-6P	208769-23-7P
208769-26-0P	208769-28-2P	208769-30-6P	208769-32-8P
208769-33-9P	208769-34-0P	208769-35-1P	208769-36-2P
208769-37-3P	208769-38-4P	208769-39-5P	208769-40-8P
208769-41-9P	208769-42-0P	208769-45-3P	208769-46-4P
208769-47-5P	208769-48-6P	208769-49-7P	208769-50-0P
208769-52-2P	208769-53-3P	208769-55-5P	208769-56-6P
208769-57-7P	208769-58-8P	208769-59-9P	208769-60-2P
208769-61-3P	208769-62-4P	208769-63-5P	208769-64-6P
208769-66-8P	208769-67-9P	208769-68-0P	208769-69-1P
208769-70-4P	208769-71-5P	208769-72-6P	208769-73-7P
208769-74-8P	208769-75-9P	208769-76-0P	208769-77-1P
208769-78-2P	208769-79-3P	208769-80-6P	208769-81-7P
208769-82-8P	208769-83-9P	208769-84-0P	208769-85-1P
208769-87-3P	208769-88-4P	208769-89-5P	208769-90-8P
208769-91-9P	208769-92-0P	208769-93-1P	208769-94-2P
208769-95-3P	208769-96-4P	208769-97-5P	208769-98-6P
208769-99-7P	208770-00-7P	208770-01-8P	208770-02-9P
208770-04-1P	208770-05-2P	208770-06-3P	208770-09-6P
208770-11-0P	208770-12-1P	208770-13-2P	208770-14-3P
208770-15-4P	208770-16-5P	208770-17-6P	208770-18-7P
208770-19-8P	208770-20-1P	208770-21-2P	208770-22-3P
208770-23-4P	208770-24-5P	208770-25-6P	208770-26-7P
208770-27-8P	208770-28-9P	208770-29-0P	208770-30-3P
208770-31-4P	208770-32-5P	208770-33-6P	208770-34-7P
208770-35-8P	208770-36-9P	208770-37-0P	208770-38-1P
208770-39-2P	208770-40-5P	208770-41-6P	208770-42-7P
208770-43-8P	208770-44-9P	208770-45-0P	208770-46-1P
208770-47-2P	208770-48-3P	208770-49-4P	208770-50-7P
208770-51-8P			

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzamide derivs. having a vasopressin antagonistic activity)

IT	208770-53-0P	208770-54-1P	208770-55-2P	208770-56-3P
	208770-57-4P	208770-58-5P	208770-59-6P	208770-60-9P
	208770-61-0P	208770-62-1P	208770-63-2P	208770-64-3P
	208770-66-5P	208770-67-6P	208770-68-7P	208770-69-8P
	208770-70-1P	208770-71-2P	208770-72-3P	208770-73-4P
	208770-74-5P	208770-75-6P	208770-76-7P	208770-77-8P
	208770-78-9P	208770-79-0P	208770-80-3P	208770-81-4P
	208770-82-5P	208770-83-6P	208770-84-7P	208770-85-8P
	208770-87-0P	208770-89-2P	208770-90-5P	208770-91-6P
	208770-92-7P	208770-93-8P	208770-94-9P	208770-95-0P
	208770-96-1P	208770-97-2P	208770-98-3P	208770-99-4P
	208771-00-0P	208771-01-1P	208771-02-2P	208771-03-3P
	208771-04-4P	208771-05-5P	208771-06-6P	208771-07-7P
	208771-08-8P	208771-09-9P	208771-10-2P	208771-11-3P
	208771-12-4P	208771-13-5P	208771-14-6P	208771-15-7P
	208771-16-8P	208771-17-9P	208771-18-0P	208771-19-1P
	208771-20-4P	208771-21-5P	208771-22-6P	208771-23-7P
	208771-24-8P	208771-25-9P	208771-26-0P	208771-27-1P
	208771-28-2P	208771-29-3P	208771-30-6P	208771-31-7P
	208771-32-8P	208771-33-9P	208771-34-0P	208771-35-1P
	208771-36-2P	208771-37-3P	208771-38-4P	208771-39-5P

208771-40-8P	208771-41-9P	208771-42-0P	208771-43-1P
208771-44-2P	208771-45-3P	208771-46-4P	208771-47-5P
208771-48-6P	208771-49-7P	208771-50-0P	208771-51-1P
208771-52-2P	208771-53-3P	208771-54-4P	208771-55-5P
208771-56-6P	208771-57-7P	208771-58-8P	208771-59-9P
208771-60-2P	208771-61-3P	208771-62-4P	208771-63-5P
208771-64-6P	208771-65-7P	208771-66-8P	208771-67-9P
208771-68-0P	208771-69-1P	208771-70-4P	208771-71-5P
208771-72-6P	208771-73-7P	208771-74-8P	208771-75-9P
208771-76-0P	208771-77-1P	208771-78-2P	208771-79-3P
208771-80-6P	208771-81-7P	208771-83-9P	208771-84-0P
208771-85-1P	208771-86-2P	208771-87-3P	208771-88-4P
208771-89-5P			

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation);
USES (Uses)

(preparation of benzamide derivs. having a vasopressin antagonistic activity)

IT 85-41-6, Phthalimide 96-48-0, Butyrolactone 98-59-9,
p-Toluenesulfonyl chloride 108-00-9 109-01-3,
N-Methylpiperazine 110-91-8, Morpholine, reactions 288-32-4,
Imidazole, reactions 541-41-3, Ethyl chloroformate 548-93-6,
2-Amino-3-hydroxybenzoic acid 570-23-0 606-18-8 2124-55-2,
Indole-4-carboxylic acid 2687-25-4, 2,3-Diaminotoluene
3694-52-8 4885-03-4 5394-18-3, N-(4-Bromobutyl)phthalimide
6780-38-7 6994-25-8 14254-57-0, Isonicotinoyl chloride
15965-55-6 18522-95-7, Ethyl N-methyloxamate 18997-19-8,
Chloromethyl pivalate 19810-31-2 24370-22-7 33265-60-0
37466-88-9 39830-66-5 57260-71-6 61063-11-4
67449-23-4 73816-11-2 76320-88-2 78316-08-2
79463-77-7, Diphenyl N-cyanocarbonimidate 84401-11-6
136285-65-9 162046-51-7 170648-89-2 172092-29-4
186662-85-1 208774-33-8 208774-37-2 208774-38-3
208774-46-3 208774-47-4 208774-50-9 208774-55-4
208774-57-6 208774-59-8 208774-62-3 208774-66-7
208774-67-8 208774-68-9

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of benzamide derivs. having a vasopressin antagonistic activity)

IT 3416-93-1P 6025-60-1P 53462-88-7P 62208-63-3P 62882-10-4P
63478-10-4P 84946-21-4P 88186-34-9P 90418-81-8P
90915-72-3P 99876-57-0P 99876-60-5P 99876-61-6P
99876-68-3P 101237-08-5P 114936-07-1P 123892-69-3P
124340-85-8P 124340-89-2P 124340-93-8P 136616-60-9P
167479-16-5P 177212-93-0P 180605-36-1P 208771-90-8P
208771-91-9P 208771-92-0P 208771-93-1P 208771-94-2P
208771-95-3P 208771-96-4P 208771-97-5P 208771-98-6P
208771-99-7P 208772-00-3P 208772-01-4P 208772-02-5P
208772-03-6P 208772-04-7P 208772-05-8P 208772-06-9P
208772-07-0P 208772-08-1P 208772-09-2P 208772-10-5P
208772-11-6P 208772-12-7P 208772-13-8P 208772-14-9P
208772-15-0P 208772-16-1P 208772-17-2P 208772-18-3P
208772-19-4P 208772-20-7P 208772-21-8P 208772-22-9P
208772-23-0P, 4-Benzoxazolecarboxylic acid 208772-24-1P,
7-Benzoxazolecarboxylic acid 208772-25-2P 208772-26-3P
208772-27-4P 208772-28-5P 208772-29-6P 208772-30-9P
208772-31-0P 208772-32-1P 208772-33-2P 208772-34-3P
208772-35-4P 208772-36-5P 208772-37-6P 208772-38-7P
208772-39-8P 208772-40-1P 208772-41-2P 208772-42-3P
208772-43-4P 208772-44-5P 208772-45-6P 208772-46-7P
208772-47-8P 208772-48-9P 208772-49-0P 208772-50-3P

208772-51-4P	208772-52-5P	208772-53-6P	208772-54-7P
208772-55-8P	208772-56-9P	208772-57-0P	208772-58-1P
208772-59-2P	208772-60-5P	208772-61-6P	208772-62-7P
208772-63-8P	208772-64-9P	208772-65-0P	208772-66-1P
208772-67-2P	208772-68-3P	208772-69-4P	208772-70-7P
208772-71-8P	208772-72-9P	208772-73-0P	208772-74-1P
208772-75-2P	208772-76-3P	208772-77-4P	208772-78-5P
208772-79-6P	208772-80-9P	208772-81-0P	208772-82-1P
208772-83-2P	208772-84-3P	208772-85-4P	208772-86-5P
208772-87-6P	208772-88-7P	208772-89-8P	208772-90-1P
208772-91-2P	208772-92-3P	208772-93-4P	208772-94-5P
208772-95-6P	208772-96-7P	208772-97-8P	208772-98-9P
208772-99-0P	208773-00-6P	208773-01-7P	208773-02-8P
208773-03-9P	208773-04-0P	208773-05-1P	208773-06-2P
208773-07-3P	208773-08-4P	208773-09-5P	208773-10-8P
208773-11-9P	208773-12-0P	208773-13-1P	208773-14-2P
208773-15-3P	208773-16-4P	208773-17-5P	208773-18-6P
208773-19-7P	208773-20-0P	208773-21-1P	208773-22-2P
208773-23-3P	208773-24-4P	208773-25-5P	208773-26-6P
208773-27-7P	208773-29-9P	208773-30-2P	208773-31-3P
208773-32-4P	208773-33-5P	208773-34-6P	208773-35-7P
208773-36-8P	208773-37-9P	208773-38-0P	208773-39-1P
208773-40-4P	208773-41-5P	208773-42-6P	208773-43-7P
208773-44-8P	208773-46-0P	208773-48-2P	208773-49-3P
208773-50-6P	208773-51-7P	208773-53-9P	208773-56-2P
208773-57-3P	208773-59-5P	208773-60-8P	208773-62-0P
208773-63-1P	208773-65-3P	208773-66-4P	208773-67-5P
208773-68-6P	208773-69-7P	208773-70-0P	208773-71-1P
208773-72-2P	208773-73-3P	208773-74-4P	208773-75-5P
208773-76-6P	208773-79-9P	208773-81-3P	208773-83-5P
208773-85-7P	208773-87-9P	208773-88-0P	208773-90-4P
208773-91-5P	208773-92-6P	208773-93-7P	208773-94-8P
208773-95-9P	208773-96-0P	208773-97-1P	208773-98-2P
208773-99-3P	208774-00-9P	208774-01-0P	208774-02-1P
208774-03-2P	208774-04-3P	208774-05-4P	208774-06-5P
208774-07-6P	208774-08-7P	208774-09-8P	208774-10-1P
208774-11-2P	208774-12-3P	208774-13-4P	208774-14-5P
208774-15-6P	208774-16-7P	208774-17-8P	

RL: RCT (Reactant); SPN (Synthetic preparation); PREP


(Preparation); RACT (Reactant or reagent)

(preparation of benzamide derivs. having a vasopressin antagonistic activity)

L177 ANSWER 4 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN

1986:583620 Document No. 105:183620 Synthesis of piperidine derivatives with a quinazoline ring system as potential antihypertensive agents. Takai, Haruki; Obase, Hiroyuki; Teranishi, Masayuki; Karasawa, Akira; Kubo, Kazuhiro; Shuto, Katsuichi; Kasuya, Yutaka; Shigenobu, Koki (Tokyo Res. Lab., Kyowa Hakko Kogyo Co., Ltd., Tokyo, 194, Japan). Chemical & Pharmaceutical Bulletin, 34(5), 1907-16 (English) 1986. CODEN: CPBTAL. ISSN: 0009-2363. OTHER SOURCES: CASREACT 105:183620.

GI



I, $RR^1 = OCH_2O$, $n=0$, $Y=O$

II, $R=Cl$, $R^1=H$, $n=1$, $Y=H_2$

AB A series of piperidine derivs. with a 2-oxo-1,2,3,4-tetrahydroquinazoline or 2,4-dioxo-1,2,3,4-tetrahydroquinazoline ring at the 4-position were prepared and tested for antihypertensive activity in rats. Among the compds tested, I [92311-03-0] and II [92311-10-9] produced relatively strong hypotension in the spontaneously hypertensive rat model.


IT 83425-18-7P 92310-95-7P 92310-96-8P
92310-97-9P 92310-98-0P 92310-99-1P
92311-00-7P 92311-01-8P 92311-02-9P
92311-03-0P 92311-04-1P 92311-05-2P
92311-06-3P 104260-16-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and antihypertensive activity of)


RN 83425-18-7 HCAPLUS

CN 2,4(1H,3H)-Quinazolin-2-one, 3-[1-[2-(3,4-dimethoxyphenyl)-1-methyl-2-oxoethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 92310-95-7 HCAPLUS

CN 2,4(1H,3H)-Quinazolin-2-one, 3-[1-[2-(3,4-dimethoxyphenyl)-2-oxoethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 92310-96-8 HCAPLUS

CN 2,4(1H,3H)-Quinazolin-2(1H)-one, 3-[1-[2-(1,3-benzodioxol-5-yl)-2-oxoethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 92310-97-9 HCAPLUS

CN 2,4(1H,3H)-Quinazolin-2(1H)-one, 6-chloro-3-[1-[2-(3,4-dimethoxyphenyl)-2-oxoethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 92310-98-0 HCAPLUS

CN 2,4(1H,3H)-Quinazolin-2(1H)-one, 3-[1-[2-(1,3-benzodioxol-5-yl)-2-oxoethyl]-4-piperidinyl]-6-chloro- (9CI) (CA INDEX NAME)




RN 92310-99-1 HCAPLUS

CN 2,4(1H,3H)-Quinazolin-2(1H)-one, 3-[1-[2-(3,4-dimethoxyphenyl)-2-oxoethyl]-4-piperidinyl]-6-nitro- (9CI) (CA INDEX NAME)




RN 92311-00-7 HCAPLUS

CN 2,4(1H,3H)-Quinazolin-2-one, 3-[1-[2-(1,3-benzodioxol-5-yl)-2-oxoethyl]-4-piperidinyl]-6-nitro- (9CI) (CA INDEX NAME)




RN 92311-01-8 HCAPLUS

CN 2,4(1H,3H)-Quinazolin-2-one, 3-[1-[2-(3,4-dimethoxyphenyl)-2-hydroxyethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 92311-02-9 HCAPLUS

CN 2,4(1H,3H)-Quinazolin-2-one, 3-[1-[2-(3,4-dimethoxyphenyl)-2-hydroxy-1-methylethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 92311-03-0 HCAPLUS

CN 2,4(1H,3H)-Quinazolin-2-one, 3-[1-[2-(1,3-benzodioxol-5-yl)-2-hydroxyethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 92311-04-1 HCAPLUS

CN 2,4(1H,3H)-Quinazolin-2-one, 6-chloro-3-[1-[2-(3,4-dimethoxyphenyl)-2-hydroxyethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 92311-05-2 HCAPLUS

CN 2,4(1H,3H)-Quinazolin-2-one, 6-chloro-3-[1-[2-(1,3-benzodioxol-5-yl)-2-hydroxyethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 92311-06-3 HCAPLUS


CN 2,4(1H,3H)-Quinazolin-2-one, 6-chloro-3-[1-(2-hydroxy-2-phenylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 104260-16-4 HCAPLUS

CN 2,4(1H,3H)-Quinazolin-2-one, 6-chloro-3-[1-(2-oxo-2-phenylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

piperidinyl]- (9CI) (CA INDEX NAME)




IT 104260-19-7P 104260-20-0P 104260-21-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and condensation with bromoketones)


RN 104260-19-7 HCAPLUS

CN 2,4(1H,3H)-Quinazolinedione, 3-(4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 104260-20-0 HCAPLUS

CN 2,4(1H,3H)-Quinazolinedione, 6-chloro-3-(4-piperidinyl)- (9CI)
(CA INDEX NAME)



RN 104260-21-1 HCAPLUS

CN 2,4(1H,3H)-Quinazolinedione, 6-nitro-3-(4-piperidinyl)- (9CI) (CA INDEX NAME)




IT 104260-17-5P 104260-18-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclization of)


RN 104260-17-5 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[2-[(ethoxycarbonyl)amino]benzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 104260-18-6 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[5-chloro-2-[(ethoxycarbonyl)amino]benzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




IT 83425-16-5P 83425-17-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and ethylcarboxylation of)


RN 83425-16-5 HCAPLUS

CN Benzamide, 2-amino-N-[1-(phenylmethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)



RN 83425-17-6 HCAPLUS

CN Benzamide, 2-amino-5-chloro-N-[1-(phenylmethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)




IT 83425-12-1P 83425-14-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); **RACT (Reactant or reagent)** (preparation and hydrolysis of)


RN 83425-12-1 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-(6-chloro-1,4-dihydro-2,4-dioxo-3(2H)-quinazolinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 83425-14-3 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-(1,4-dihydro-6-nitro-2,4-dioxo-3(2H)-quinazolinyl)-, ethyl ester (9CI) (CA INDEX NAME)




IT 83425-10-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); **RACT (Reactant or reagent)** (preparation and hydrolysis or nitration of)

RN 83425-10-9 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-(1,4-dihydro-2,4-dioxo-3(2H)-quinazolinyl)-, ethyl ester (9CI) (CA INDEX NAME)



- CC 1-8 (Pharmacology)
Section cross-reference(s): 28
- IT 70-11-1 1835-02-5 1835-05-8 40288-65-1
RL: BIOL (Biological study)
(condensation of, with (tetrahydroquinazolinyl)piperi
dines)
- IT 118-48-9
RL: BIOL (Biological study)
(condensation of, with benzylaminopiperidine
dihydrochloride)
- IT 4743-17-3
RL: BIOL (Biological study)
(condensation of, with benzylaminopiperidine
dihydrochloride)
- IT 1205-72-7
RL: BIOL (Biological study)
(condensation of, with isatoic anhydride)
- IT 110-89-4DP, quinazoline derivs. 253-82-7DP, piperidine derivs.
83425-18-7P 92310-95-7P 92310-96-8P
92310-97-9P 92310-98-0P 92310-99-1P
92311-00-7P 92311-01-8P 92311-02-9P
92311-03-0P 92311-04-1P 92311-05-2P
92311-06-3P 92311-07-4P 92311-08-5P 92311-09-6P
92311-10-9P 92311-13-2P 92311-14-3P 92311-15-4P
92311-16-5P 92311-17-6P 92311-18-7P 92311-19-8P
92338-59-5P 104260-16-4P
RL: BAC (Biological activity or effector, except adverse); BSU
(Biological study, unclassified); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation);
USES (Uses)
(preparation and antihypertensive activity of)
- IT 92311-29-0P 104260-19-7P 104260-20-0P
104260-21-1P 104260-24-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and condensation with bromoketones)
- IT 104260-17-5P 104260-18-6P 104260-23-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP
(Preparation); RACT (Reactant or reagent)
(preparation and cyclization of)
- IT 83425-16-5P 83425-17-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and ethylcarboxylation of)
- IT 83425-12-1P 83425-14-3P 92311-28-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP
(Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis of)
- IT 83425-10-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP
(Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis or nitration of)

L177 ANSWER 5 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN

1986:68856 Document No. 104:68856 Bicyclic heterocyclyl containing N-(bicyclic heterocyclyl)-4-piperidinamines. Janssens, Frans Eduard; Torremans, Joseph Leo Ghislanus; Hens, Jozef Francis; Van Offenwert, Theophilus Theresia J. M. (Janssen Pharmaceutica N. V., Belg.). Eur. Pat. Appl. EP 144101 A2 19850612, 106 pp. DESIGNATED STATES: R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE. (English). CODEN: EPXXDW. APPLICATION: EP 1984-201611 19841107. PRIORITY: US 1983-556742 19831130; US 1984-660608 19841012.

GI For diagram(s), see printed CA Issue.



AB The title compds. [I; R = H, cycloalkyl, pyridinyl, pyrazinyl, alkyl-(un)substituted furanyl, thiazolyl, imidazolyl, halo-(un)substituted thienyl, (un)substituted alkyl, Ph; R1 = H, alkyl, cycloalkyl, alkanoyl, alkoxy carbonyl, (un)substituted phenylalkyl; R2 = H, alkyl; R3 = alkyl, pyrrolidinyl, piperidinyl, homopiperonyl, each substituted by a group containing a bicyclic heterocyclic moiety; X = atoms required to complete an (un)substituted C6H6 or pyridine ring] (>150 in all) were prepared. Thus, 1-[(4-fluorophenyl)methyl]-N-(4-piperidinyl)-1H-benzimidazol-2-amine was alkylated by heating at 70° with 6-(2-bromoethyl)-3,7-dimethyl-5H-thiazolo[3,2-a]pyrimidin-5-one-HBr in DMF containing Na2CO3 to give 62.8% II. II had antihistaminic activity in rats, counteracting the lethality of compound 48/80 with an ED50 of 0.31 mg/kg s.c. or orally, and inhibiting gastric lesions caused by the same agent with an ED50 of 0.63 mg/kg orally.

IT 99138-99-5

RL: RCT (Reactant); RACT (Reactant or reagent) (cyclization of)

RN 99138-99-5 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[2-[[[4-(4-fluorophenyl)methyl]amino]-5-methylphenyl]amino]thioxomethyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




IT 99158-53-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and aminolysis of, by piperidine derivative)

RN 99158-53-9 HCAPLUS

CN 2,4(1H,3H)-Quinazolin-2-one, 3-(2-chloroethyl)-1-methyl- (9CI) (CA INDEX NAME)




IT 99156-63-5P 99156-67-9P 99156-70-4P
 99156-71-5P 99156-72-6P 99156-87-3P
 99156-88-4P 99156-89-5P 99156-92-0P
 99156-93-1P 99156-95-3P 99156-96-4P
 99156-97-5P 99156-98-6P 99156-99-7P
 99157-00-3P 99157-01-4P 99157-02-5P
 99157-05-8P 99157-08-1P 99157-09-2P
 99157-10-5P 99157-48-9P 99157-49-0P
 99157-88-7P 99157-89-8P 99157-90-1P
 99157-91-2P 99157-92-3P 99157-98-9P
 99195-10-5P 99195-19-4P 99195-21-8P
 99436-25-6P

RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); SPN (Synthetic preparation);
 BIOL (Biological study); PREP (Preparation)
 (preparation and antihistaminic activity of)


RN 99156-63-5 HCAPLUS

CN 2,4(1H,3H)-Quinazolin-2-one, 3-[2-[4-[[1-[(4-fluorophenyl)methyl]-
 1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]- (9CI) (CA INDEX
 NAME)




RN 99156-67-9 HCAPLUS

CN 1H-Purine-2,6-dione, 1-[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-
 benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]-3,7-dihydro-3,7-
 dimethyl- (9CI) (CA INDEX NAME)




RN 99156-70-4 HCAPLUS
 CN 1H-Purine-2,6-dione, 1-[2-[4-[[1-(2-furanylmethyl)-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]-3,7-dihydro-3,7-dimethyl- (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 99156-71-5 HCAPLUS

CN 1H-Purine-2,6-dione, 1-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-3,7-dihydro-3,7-dimethyl- (9CI) (CA INDEX NAME)




RN 99156-72-6 HCAPLUS

CN 1H-Purine-2,6-dione, 1-[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]-3,7-dihydro-3,7-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 99156-87-3 HCAPLUS
 CN 2,4(1H,3H)-Quinazolin-2-one, 3-[2-[4-[[1-(2-furanylmethyl)-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 99156-88-4 HCAPLUS
 CN 2,4(1H,3H)-Quinazolin-2-one, 3-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 99156-89-5 HCAPLUS

CN 2,4-(1H,3H)-Quinazolin-2-one, 3-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 99156-92-0 HCAPLUS

CN 2,4(1H,3H)-Quinazolin-2-one, 3-[3-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]propyl]hexahydro- (9CI)
(CA INDEX NAME)




RN 99156-93-1 HCAPLUS

CN 2,4(1H,3H)-Quinazolin-2-one, 3-[3-[4-[[1-(2-furanylmethyl)-1H-benzimidazol-2-yl]amino]-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)




RN 99156-95-3 HCAPLUS

CN 2,4(1H,3H)-Quinazolin-2(1H)-one, 3-[[3-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]propyl]- (9CI)
(CA INDEX NAME)




RN 99156-96-4 HCAPLUS

CN 2,4(1H,3H)-Quinazolin-2(1H)-one, 3-[[2-[[1-[[4-(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]-1-methyl]- (9CI)
(CA INDEX NAME)



RN 99156-97-5 HCAPLUS


CN 2,4(1H,3H)-Quinazolin-2(1H)-one, 3-[[2-[[1-[[4-(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]-1-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 99156-98-6 HCAPLUS

CN 2,4(1H,3H)-Quinazolinedione, 3-[2-[4-[[1-(2-furanylmethyl)-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 99156-99-7 HCAPLUS

CN 2,4(1H,3H)-Quinazolinedione, 3-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]hexahydro-1-methyl- (9CI) (CA INDEX NAME)




RN 99157-00-3 HCAPLUS

CN 2,4(1H,3H)-Quinazolin-2-one, 3-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 99157-01-4 HCAPLUS


CN 2,4(1H,3H)-Quinazolin-2-one, 3-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-1-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 99157-02-5 HCAPLUS

CN 2,4(1H,3H)-Quinazolin-2-one, 3-[3-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)




RN 99157-05-8 HCAPLUS
 CN 1H-Purine-2,6-dione, 7-[2-[4-[[1-(2-furanylmethyl)-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]-3,7-dihydro-1,3-dimethyl- (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 99157-08-1 HCAPLUS
 CN 1H-Purine-2,6-dione, 7-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-3,7-dihydro-1,3-

dimethyl- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 99157-09-2 HCAPLUS
 CN 1H-Purine-2,6-dione, 7-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-3,7-dihydro-1,3-dimethyl- (9CI) (CA INDEX NAME)



RN 99157-10-5 HCAPLUS


CN 1H-Purine-2,6-dione, 7-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-3,7-dihydro-1,3-dimethyl-, dihydrobromide (9CI) (CA INDEX NAME)




●2 HBr

RN 99157-48-9 HCAPLUS


CN 2,4(1H,3H)-Quinazolin-2(1H)-one, 3-[2-[4-[[3-(2-thienylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 99157-49-0 HCAPLUS
 CN 2,4(1H,3H)-Quinazolin-2(1H)-one, 3-[2-[4-[[3-[(5-methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 99157-88-7 HCAPLUS
 CN Carbamic acid, [1-[2-(1-ethyl-1,4-dihydro-2,4-dioxo-3(2H)-quinazolinyl)ethyl]-4-piperidinyl][1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 99157-89-8 HCAPLUS
 CN 2,4(1H,3H)-Quinazolin-2(1H)-one, 1-ethyl-3-[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-

piperidinylethyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 99157-90-1 HCAPLUS
 CN 2,4(1H,3H)-Quinazolin-2-one, 1-ethyl-3-[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinylethyl]- (9CI) (CA INDEX NAME)




RN 99157-91-2 HCAPLUS
 CN 2,4(1H,3H)-Quinazolin-2-one, 3-[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinylethyl]-6-(methylthio)- (9CI) (CA INDEX NAME)




RN 99157-92-3 HCAPLUS

CN 2,4(1H,3H)-Quinazolin-2-one, 3-[4-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]butyl]- (9CI) (CA INDEX NAME)




RN 99157-98-9 HCAPLUS

CN Thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione, 3-[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 99195-10-5 HCAPLUS

CN 1H-Purine-2,6-dione, 7-[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]-3,7-dihydro-1,3-dimethyl- (9CI) (CA INDEX NAME)




RN 99195-19-4 HCAPLUS

CN 2,4(1H,3H)-Quinazolinedione, 3-[4-[4-[[1-(2-furanylmethyl)-1H-benzimidazol-2-yl]amino]-1-piperidinyl]butyl]- (9CI) (CA INDEX NAME)




RN 99195-21-8 HCAPLUS
CN Thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione, 3-[2-[4-[[1-(2-furanylmethyl)-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]-6-methyl- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A



RN 99436-25-6 HCAPLUS
CN 2,4(1H,3H)-Quinazolin-2(1H)-one, 3-[2-[4-[[3-(3-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)




IT 99158-52-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and chlorination of)

RN 99158-52-8 HCAPLUS

CN 2,4 (1H,3H)-Quinazolinedione, 3-(2-hydroxyethyl)-1-methyl- (9CI)
(CA INDEX NAME)



IT 99158-38-0P 99158-40-4P 99158-41-5P


99158-42-6P 99158-43-7P 99158-44-8P

99158-45-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and cyclocondensation reaction of)


RN 99158-38-0 HCAPLUS

CN Benzamide, 2-amino-N-[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 99158-40-4 HCAPLUS

CN Benzamide, N-[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]-2-(methylamino)- (9CI) (CA INDEX NAME)




RN 99158-41-5 HCAPLUS

CN Benzamide, 2-amino-N-[2-[4-[[1-(2-furanylmethyl)-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 99158-42-6 HCAPLUS

CN Benzamide, N-[2-[4-[[1-(2-furanylmethyl)-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]-2-(methylamino)- (9CI) (CA INDEX NAME)




RN 99158-43-7 HCAPLUS


CN Benzamide, 2-amino-N-[4-[4-[[1-(2-furanylmethyl)-1H-benzimidazol-2-yl]amino]-1-piperidinyl]butyl]- (9CI) (CA INDEX NAME)



RN 99158-44-8 HCAPLUS
 CN Benzamide, 2-amino-N-[4-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]butyl]- (9CI) (CA INDEX NAME)



RN 99158-45-9 HCAPLUS
 CN Benzamide, 2-amino-N-[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]-5-(methylthio)- (9CI) (CA INDEX NAME)



IC ICM C07D401-12
 ICS C07D401-14; C07D405-12; C07D405-14; C07D409-12; C07D409-14;
 C07D417-14; C07D471-04; C07D487-04; C07D513-04; C07D519-00
 CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1, 63
 IT 54-96-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (condensation of, with (isothiocyanatoethyl)piperidine
 e derivs.)
 IT 75-15-0, reactions 2719-30-4.
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (condensation of, with aminopiperidinecarboxylate)

derivative)
IT 58859-46-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(condensation of, with carbon disulfide)
IT 90539-29-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(condensation of, with isothiocyanatonitrobenzene)
IT 90518-36-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(condensation of, with isothiocyanatopiperidine
derivative)
IT 90518-39-1 90518-40-4 90518-44-8 90518-45-9 99138-96-2
99138-98-4 99138-99-5 99158-24-4 99158-63-1
99158-64-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(cyclization of)
IT 99158-49-3P 99158-50-6P 99158-53-9P 99158-54-0P
99158-57-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP
(Preparation); RACT (Reactant or reagent)
(preparation and aminolysis of, by piperidine derivative)
IT 99156-62-4P 99156-63-5P 99156-64-6P 99156-65-7P
99156-66-8P 99156-67-9P 99156-68-0P 99156-69-1P
99156-70-4P 99156-71-5P 99156-72-6P
99156-73-7P 99156-74-8P 99156-75-9P 99156-76-0P
99156-77-1P 99156-78-2P 99156-79-3P 99156-80-6P
99156-81-7P 99156-82-8P 99156-83-9P 99156-84-0P
99156-85-1P 99156-86-2P 99156-87-3P
99156-88-4P 99156-89-5P 99156-90-8P
99156-91-9P 99156-92-0P 99156-93-1P
99156-94-2P 99156-95-3P 99156-96-4P
99156-97-5P 99156-98-6P 99156-99-7P
99157-00-3P 99157-01-4P 99157-02-5P
99157-03-6P 99157-04-7P 99157-05-8P 99157-06-9P
99157-07-0P 99157-08-1P 99157-09-2P
99157-10-5P 99157-11-6P 99157-12-7P 99157-13-8P
99157-14-9P 99157-15-0P 99157-16-1P 99157-17-2P
99157-18-3P 99157-19-4P 99157-20-7P 99157-21-8P
99157-22-9P 99157-23-0P 99157-24-1P 99157-25-2P
99157-26-3P 99157-27-4P 99157-28-5P 99157-29-6P
99157-30-9P 99157-31-0P 99157-32-1P 99157-33-2P
99157-34-3P 99157-35-4P 99157-36-5P 99157-37-6P
99157-38-7P 99157-39-8P 99157-40-1P 99157-41-2P
99157-42-3P 99157-43-4P 99157-44-5P 99157-45-6P
99157-46-7P 99157-47-8P 99157-48-9P
99157-49-0P 99157-50-3P 99157-51-4P 99157-52-5P
99157-53-6P 99157-54-7P 99157-55-8P 99157-56-9P
99157-57-0P 99157-58-1P 99157-59-2P 99157-60-5P
99157-61-6P 99157-62-7P 99157-63-8P 99157-64-9P
99157-65-0P 99157-66-1P 99157-67-2P 99157-68-3P
99157-69-4P 99157-70-7P 99157-71-8P 99157-72-9P
99157-73-0P 99157-74-1P 99157-75-2P 99157-76-3P
99157-77-4P 99157-78-5P 99157-79-6P 99157-80-9P
99157-81-0P 99157-82-1P 99157-83-2P 99157-84-3P
99157-85-4P 99157-86-5P 99157-87-6P 99157-88-7P
99157-89-8P 99157-90-1P 99157-91-2P
99157-92-3P 99157-93-4P 99157-94-5P 99157-95-6P
99157-96-7P 99157-97-8P 99157-98-9P 99157-99-0P
99158-00-6P 99158-01-7P 99158-02-8P 99158-03-9P
99158-04-0P 99158-05-1P 99158-06-2P 99158-07-3P
99158-08-4P 99158-09-5P 99158-10-8P 99158-11-9P
99158-12-0P 99158-13-1P 99158-14-2P 99158-15-3P

99158-16-4P 99158-17-5P 99158-18-6P 99195-10-5P
 99195-11-6P 99195-12-7P 99195-13-8P 99195-14-9P
 99195-15-0P 99195-16-1P 99195-17-2P 99195-18-3P
 99195-19-4P 99195-20-7P 99195-21-8P
 99195-22-9P 99228-02-1P 99228-03-2P 99436-25-6P
 99436-26-7P 99436-27-8P 99455-64-8P 101637-70-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (preparation and antihistaminic activity of)

- IT 99158-52-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and chlorination of)
- IT 73733-70-7P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation and condensation of, with benzene- and pyridinediamines)
- IT 73736-79-5P 99151-17-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and condensation of, with heterocyclic amines)
- IT 90518-32-4P 90518-33-5P 99138-92-8P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation and condensation of, with isothiocyantopiperidine derivative)
- IT 99158-30-2P 99158-36-8P 99158-37-9P 99158-38-0P
 99158-40-4P 99158-41-5P 99158-42-6P
 99158-43-7P 99158-44-8P 99158-45-9P
 99158-46-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and cyclocondensation reaction of)

L177 ANSWER 6 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN

1986:50874 Document No. 104:50874 N-(4-Piperidinyl) bicyclic condensed 2-imidazolamine derivatives. Janssens, Frans Eduard; Torremans, Joseph Leo Ghislanus; Hens, Jozef Francis; Van Offenwert, Theophilus Theresia Joannes (Janssen Pharmaceutica N. V., Belg.). Eur. Pat. Appl. EP 151824 A2 19850821, 68 pp. DESIGNATED STATES: R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE. (English). CODEN: EPXXDW. APPLICATION: EP 1984-201812 19841206. PRIORITY: US 1984-569115 19840109; US 1984-660670 19841015.


GI For diagram(s), see printed CA Issue.

AB The title compds. [I; A = (un)substituted C₆H₆ or pyridine ring; R = H, alkyl; R₁ = H, alkyl, cycloalkyl, aralkyl, (alkyl)furanyl, (alkyl)imidazolyl, (halo)thienyl, pyridinyl, pyrazinyl, thiazolyl, (un)substituted Ph; R₂ = H, alkyl, cycloalkyl, aralkyl, alkanoyl, alkoxy carbonyl; R₃ = R₄Z, (un)substituted saturated heterocyclyl; R₄ = acyl, acylamino, acyloxy, acylthio, (un)substituted Ph, aryl, etc.; Z = alkylene] were prepared. Thus 3-chloro-2-nitropyridine was aminolyzed with 4-FC₆H₄CH₂NH₂ and the product hydrogenated to give N3-[(4-fluorophenyl)methyl]-2,3-pyridinediamine. This was condensed with Et 4-isothiocyantopiperidinecarboxylate to give pyridinylthiourea derivative II which was cyclized by heating in EtOH with HgO and S to give imidazopyridinamine III (R₅ = CO₂Et). The latter was decarboxylated by heating in 48% aqueous HBr to give III.2HBr (R₅ = H) which was alkylated with a p-methoxyphenethyl halide to give III (R₅ = 4-MeOC₆H₄CH₂CH₂) (IV). I are antihistaminics. In mice IV inhibited compound 48/80-induced lethality with an ED₅₀ of 0.08 mg/kg s.c. or orally.

IT 700-03-8

RL: RCT (Reactant); RACT (Reactant or reagent)
(chlorination of)


RN 700-03-8 HCAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 3-(2-hydroxyethyl)- (9CI) (CA INDEX
NAME)


IT 99158-38-0P 99780-70-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP
(Preparation); RACT (Reactant or reagent)
(preparation and acetylation of)

RN 99158-38-0 HCAPLUS

CN Benzamide, 2-amino-N-[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-
benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]- (9CI) (CA INDEX
NAME)

RN 99780-70-8 HCAPLUS


CN Benzamide, 2-(ethylamino)-N-[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-
benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]- (9CI) (CA INDEX
NAME)

IT 99780-71-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP
(Preparation); RACT (Reactant or reagent)
(preparation and alkylation by, of piperidine derivs.)

RN 99780-71-9 HCAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 3-(2-chloroethyl)- (9CI) (CA INDEX
NAME)




IT 99780-47-9P 99780-48-0P 99780-49-1P
 99780-50-4P 99780-51-5P 99780-52-6P
 99780-53-7P 99780-54-8P 99780-55-9P
 99780-62-8P 99796-66-4P

RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation);
 USES (Uses)

(preparation of, as antihistaminic)


RN 99780-47-9 HCAPLUS

CN Benzamide, 2-(acetyl-amino)-N-[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-
 benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]- (9CI) (CA INDEX
 NAME)



RN 99780-48-0 HCAPLUS

CN Benzamide, 2-(acetyethyl-amino)-N-[2-[4-[[1-[(4-
 fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-
 piperidinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 99780-49-1 HCAPLUS

CN Benzamide, 2-(acetyethyl-amino)-N-[2-[4-[[1-[(4-
 fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-
 piperidinyl]ethyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX
 NAME)

CM 1


CRN 99780-48-0
 CMF C32 H37 F N6 O2




CM 2

CRN 110-17-8
 CMF C4 H4 O4


Double bond geometry as shown.



RN 99780-50-4 HCAPLUS
 CN Methanesulfonamide, N-[4-[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 99780-51-5 HCAPLUS
 CN Benzamide, N-[4-[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 99780-52-6 HCAPLUS

CN Acetamide, N-[4-[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 99780-53-7 HCAPLUS

CN Urea, [4-[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 99780-54-8 HCAPLUS

CN Urea, N-[4-[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]phenyl]-N'-methyl- (9CI) (CA INDEX NAME)




RN 99780-55-9 HCAPLUS

CN Thiourea, N-[4-[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]phenyl]-N'-methyl- (9CI) (CA INDEX NAME)




RN 99780-62-8 HCAPLUS

CN Benzamide, N-[4-[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 99796-66-4 HCAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 3-[2-[4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)



IC ICM C07D471-04
ICS C07D401-12; C07D235-30; A61K031-445
CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
IT 700-03-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(chlorination of)
IT 70-25-7 6160-65-2 55114-97-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(condensation of, with (aminoethyl)piperidine
derivs.)
IT 110-89-4, reactions 156-87-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(condensation of, with (isothiocyanatoethyl)piperidin
e derivs.)
IT 590-28-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(condensation of, with aniline derivative)
IT 39204-47-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(condensation of, with benzimidazolamine derivative)
IT 140-75-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(condensation of, with chloropyridines)
IT 50-00-0, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(condensation of, with furanmethanol and piperidine
derivative)
IT 60-23-1 1722-12-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(condensation of, with furanmethanol derivative)
IT 110-75-8 18217-00-0 20972-54-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(condensation of, with piperidine derivs.)
IT 75970-64-8 75970-99-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(condensation reactions of)
IT 99158-38-0P 99780-70-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP
(Preparation); RACT (Reactant or reagent)
(preparation and acetylation of)
IT 99780-71-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP
(Preparation); RACT (Reactant or reagent)
(preparation and alkylation by, of piperidine derivs.)
IT 73736-79-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP
(Preparation); RACT (Reactant or reagent)
(preparation and condensation of, with amines)
IT 73733-70-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and condensation of, with pyridinamines)
IT 90518-32-4P 90518-33-5P 90518-36-8P 99138-91-7P
99138-92-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and condensation of, with
thiocyanatopiperidine derivative)
IT 90518-66-4P 90518-67-5P 90518-71-1P 90518-72-2P
90518-73-3P 90518-74-4P 90518-75-5P 90518-76-6P
90518-77-7P 90518-81-3P 90518-82-4P 90519-13-4P
90519-18-9P 90519-37-2P 90539-30-3P 99139-10-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP

(Preparation); RACT (Reactant or reagent)
(preparation and **condensation** reactions of)

IT 99158-37-9P 99779-98-3P 99779-99-4P 99780-00-4P
99780-01-5P 99780-02-6P 99780-03-7P 99780-04-8P
99780-05-9P 99780-06-0P 99780-07-1P 99780-08-2P
99780-09-3P 99780-10-6P 99780-11-7P 99780-12-8P
99780-13-9P 99780-14-0P 99780-15-1P 99780-16-2P
99780-17-3P 99780-18-4P 99780-19-5P 99780-20-8P
99780-21-9P 99780-22-0P 99780-23-1P 99780-24-2P
99780-25-3P 99780-26-4P 99780-27-5P 99780-28-6P
99780-29-7P 99780-30-0P 99780-31-1P 99780-32-2P
99780-33-3P 99780-34-4P 99780-35-5P 99780-36-6P
99780-37-7P 99780-38-8P 99780-39-9P 99780-40-2P
99780-41-3P 99780-42-4P 99780-43-5P 99780-44-6P
99780-45-7P 99780-46-8P 99780-47-9P
99780-48-0P 99780-49-1P 99780-50-4P
99780-51-5P 99780-52-6P 99780-53-7P
99780-54-8P 99780-55-9P 99780-56-0P
99780-57-1P 99780-58-2P 99780-59-3P 99780-60-6P
99780-61-7P 99780-62-8P 99780-63-9P 99796-65-3P
99796-66-4P 99796-67-5P

RL: BAC (Biological activity or effector, except adverse); BSU
(Biological study, unclassified); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation);
USES (Uses)

(preparation of, as antihistaminic)


IT 29976-53-2

RL: RCT (Reactant); RACT (Reactant or reagent)
(reductive **condensation** of, with piperidine derivative)

L177 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN

1983:594812 Document No. 99:194812 N-(3-Hydroxy-4-
piperidinyl)benzamide derivatives. Van Daele, Georges (Janssen
Pharmaceutica N. V., Belg.). Eur. Pat. Appl. EP 76530 A2
19830413, 137 pp. DESIGNATED STATES: R: AT, BE, CH, DE, FR, GB,
IT, LI, LU, NL, SE. (English). CODEN: EPXXDW. APPLICATION: EP
1982-201080 19820903. PRIORITY: US 1981-307409 19811001; US
1982-403603 19820730.

GI



I


AB Piperidinybenzamides I [R = alkoxy carbonyl, (un)substituted
alkyl, cycloalkyl, aralkyl, etc.; R1 = H, alkyl, aralkyl,
aminoalkyl, alkyl carbonyl; R2 = H, alkyl; R3 = (un)substituted Ph]
(244 compds.) were prepared Thus, cis-I [R = R2 = H, R1 = Me, R3 =
5,4,2-Cl(H2N)(MeO)C6H2] was treated with 4-FC6H4O(CH2)3Cl to give
42.8% cis-I [R = 4-FC6H4O(CH2)3, R1 = Me, R2 = H, R3 =
5,4,2-Cl(H2N)(MeO)C6H2] (II). II had a min. effective concentration of
0.00016 mg/L for stimulation of contraction of isolated guinea pig
ileum.

IT 5081-87-8

RL: RCT (Reactant); RACT (Reactant or reagent)
(alkylation by, of piperidine derivs.)

RN 5081-87-8 HCAPLUS

CN 2,4(1H,3H)-Quinazolinedione, 3-(2-chloroethyl)- (7CI, 8CI, 9CI)
(CA INDEX NAME)




IT 83863-69-8

RL: RCT (Reactant); RACT (Reactant or reagent)
(alkylation of)

RN 83863-69-8 HCAPLUS

CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[(3R,4S)-3-methoxy-4-piperidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 81098-60-4P 83863-69-8P 83863-70-1P
86718-44-7P 86718-45-8P 86718-48-1P
86718-50-5P 86718-51-6P 86718-52-7P
86718-54-9P 86718-55-0P 86718-56-1P
86718-57-2P 86718-58-3P 86718-59-4P
86718-60-7P 86718-62-9P 86718-64-1P
86718-65-2P 86718-66-3P 86718-69-6P
86718-70-9P 86718-71-0P 86718-72-1P
86718-73-2P 86718-75-4P 86718-76-5P
86718-89-0P 86718-91-4P 86718-97-0P
86718-98-1P 86718-99-2P 86719-02-0P
86719-04-2P 86719-05-3P 86719-06-4P
86719-07-5P 86719-08-6P 86719-09-7P
86719-10-0P 86719-12-2P 86719-13-3P
86719-14-4P 86719-18-8P 86719-26-8P
86719-27-9P 86719-29-1P 86719-34-8P
86719-36-0P 86719-37-1P 86719-38-2P
86719-39-3P 86719-40-6P 86719-41-7P
86719-42-8P 86719-43-9P 86719-44-0P
86719-45-1P 86719-46-2P 86719-47-3P
86719-48-4P 86719-49-5P 86719-51-9P
86719-52-0P 86719-53-1P 86719-58-6P
86719-59-7P 86719-60-0P 86719-65-5P
86719-66-6P 86719-67-7P 86719-68-8P
86719-69-9P 86719-70-2P 86719-72-4P
86719-73-5P 86719-74-6P 86719-75-7P
86719-76-8P 86719-83-7P 86719-84-8P
86719-85-9P 86719-88-2P 86719-89-3P


86719-90-6P 86719-91-7P 86719-92-8P
 86719-93-9P 86719-94-0P 86719-95-1P
 86719-96-2P 86719-97-3P 86719-98-4P
 86719-99-5P 86720-04-9P 86720-05-0P
 86720-06-1P 86720-07-2P 86720-08-3P
 86720-09-4P 86720-10-7P 86720-11-8P
 86720-12-9P 86720-13-0P 86720-14-1P
 86720-15-2P 86720-16-3P 86720-17-4P
 86720-18-5P 86720-19-6P 86720-24-3P
 86720-25-4P 86720-26-5P 86720-27-6P
 86720-28-7P 86720-29-8P 86720-30-1P
 86720-39-0P 86720-41-4P 86720-42-5P
 86720-43-6P 86720-45-8P 86720-47-0P
 86720-48-1P 86720-49-2P 86720-50-5P
 86720-51-6P 86720-52-7P 86720-53-8P
 86720-54-9P 86720-55-0P 86720-56-1P
 86720-57-2P 86720-58-3P 86720-59-4P
 86720-60-7P 86720-61-8P 86720-62-9P
 86720-63-0P 86720-65-2P 86720-66-3P
 86720-67-4P 86720-68-5P 86720-69-6P
 86720-70-9P 86720-71-0P 86720-72-1P
 86720-73-2P 86720-74-3P 86720-75-4P
 86720-76-5P 86720-77-6P 86729-78-4P
 86848-63-7P 104466-82-2P 104860-19-7P
 104860-57-3P 104860-58-4P 104860-59-5P
 104860-60-8P 104860-61-9P 104860-63-1P
 104860-64-2P 104860-66-4P 104860-67-5P
 104860-68-6P 104860-69-7P 104889-57-8P
 104889-60-3P 104889-62-5P 105249-04-5P
 105249-07-8P 137472-66-3P 182008-76-0P

RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); SPN (Synthetic preparation);
 BIOL (Biological study); PREP (Preparation)
 (preparation and gastric motility activity of)

RN 81098-60-4 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[(3R,4S)-3-(4-
 fluorophenoxy)propyl]-3-methoxy-4-piperidinyl]-2-methoxy-, rel-
 (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 83863-69-8 HCAPLUS

CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[(3R,4S)-3-methoxy-4-
 piperidinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 83863-70-1 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(4-amino-5-chloro-2-methoxybenzoyl)amino]-3-methoxy-, ethyl ester, (3R,4S)-rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 86718-44-7 HCAPLUS

CN Benzamide, 4-amino-5-chloro-2-methoxy-N-(3-methoxy-4-piperidinyl)-N-methyl-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86718-45-8 HCAPLUS

CN Benzamide, 4-amino-2-methoxy-N-(3-methoxy-4-piperidinyl)-5-(methylsulfinyl)-, (3α,4α)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86718-48-1 HCAPLUS

CN 1,3-Benzenedicarboxamide, 4-amino-6-methoxy-N1-(3-methoxy-4-piperidinyl)-, cis- (9CI) (CA INDEX NAME).


Relative stereochemistry.



RN 86718-50-5 HCAPLUS

CN Benzamide, 4-amino-N-[1-[4,4-bis(4-fluorophenyl)butyl]-3-hydroxy-4-piperidinyl]-, dihydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 86718-51-6 HCAPLUS


CN Benzamide, 4-amino-N-[1-[4,4-bis(4-fluorophenyl)butyl]-3-methoxy-4-piperidinyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 86718-52-7 HCAPLUS
 CN Benzamide, 4-amino-N-[1-[4,4-bis(4-fluorophenyl)butyl]-3-hydroxy-4-piperidinyl]-2-chloro-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 86718-54-9 HCAPLUS
 CN Benzamide, 4-amino-N-[1-[4,4-bis(4-fluorophenyl)butyl]-3-methoxy-4-piperidinyl]-2-chloro-, cis-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 86718-53-8
 CMF C29 H32 Cl F2 N3 O2


Relative stereochemistry.



CM 2

CRN 144-62-7


CMF C2 H2 O4



RN 86718-55-0 HCAPLUS

CN Benzamide, 4-amino-N-[1-[3-(2-amino-4-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl]-5-chloro-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86718-56-1 HCAPLUS

CN Benzamide, 4-amino-N-[1-[3-(4-aminophenoxy)propyl]-3-methoxy-4-piperidinyl]-5-chloro-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86718-57-2 HCAPLUS

CN Benzamide, 4-amino-N-[1-[4-(2-amino-4-fluorophenoxy)cyclohexyl]-3-methoxy-4-piperidiny]-5-chloro-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86718-58-3 HCAPLUS

CN Benzamide, N-[3-(acetyloxy)-1-(2-pyridinylmethyl)-4-piperidiny]-4-amino-5-chloro-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86718-59-4 HCAPLUS

CN Benzamide, 4-(acetylamino)-N-[3-(acetyloxy)-1-[3-(4-fluorophenoxy)propyl]-4-piperidinyl]-5-chloro-2-methoxy-, cis-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86718-60-7 HCAPLUS

CN Benzamide, N-[3-(acetyloxy)-1-[3-(4-fluorophenoxy)propyl]-4-piperidinyl]-4-amino-5-chloro-2-methoxy-, cis-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86718-62-9 HCAPLUS

CN 1,3-Benzenedicarboxamide, 4-amino-N1-[1-[(4-fluorophenyl)methyl]-3-methoxy-4-piperidinyl]-6-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86718-64-1 HCAPLUS

CN 1,3-Benzenedicarboxamide, 4-amino-6-methoxy-N1-[3-methoxy-1-(phenylmethyl)-4-piperidinyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 86718-65-2 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[4-(4-fluorophenyl)butyl]-3-methoxy-4-piperidinyl]-

methoxy-4-piperidinyl]-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 86718-66-3 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[4-(4-fluorophenyl)-3-hydroxy-4-oxobutyl]-3-methoxy-4-piperidinyl]-2-methoxy- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 86718-69-6 HCAPLUS


CN Benzamide, 4-amino-5-chloro-N-[(3R,4S)-1-[3-(4-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl]-2-methoxy-, rel-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 81098-60-4

CMF C23 H29 Cl F N3 O4

Relative stereochemistry.




CM 2

CRN 110-16-7

CMF C4 H4 O4


Double bond geometry as shown.



RN 86718-70-9 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[(3R,4S)-1-[3-(4-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl]-2-methoxy-, rel-(+)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 86718-71-0 HCAPLUS


CN Benzamide, 4-amino-5-chloro-N-[(3S,4R)-1-[3-(4-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl]-2-methoxy-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 86718-70-9

CMF C23 H29 Cl F N3 O4

Absolute stereochemistry. Rotation (+).




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 86718-72-1 HCAPLUS


CN Benzamide, 4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxy-4-piperidiny]-2-methoxy-, cis-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 81098-60-4

CMF C23 H29 Cl F N3 O4


Relative stereochemistry.



CM 2

CRN 7664-93-9

CMF H2 O4 S



RN 86718-73-2 HCAPLUS


CN Benzamide, 4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxy-4-piperidiny]-2-methoxy-, cis-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 81098-60-4

CMF C23 H29 Cl F N3 O4


Relative stereochemistry.



CM 2


CRN 77-92-9
CMF C6 H8 O7

RN 86718-75-4 HCAPLUS
 CN Benzamide, 4-amino-5-chloro-N-[(3R,4S)-1-[3-(4-fluorophenoxy)propyl]-3-methoxy-1-oxido-4-piperidinyl]-2-methoxy-,
 rel- (9CI) (CA INDEX NAME)



RN 86718-76-5 HCAPLUS
 CN Piperidinium, 4-[(4-amino-5-chloro-2-methoxybenzoyl)amino]-1-[3-(4-fluorophenoxy)propyl]-3-methoxy-1-methyl-, iodide,
 (3α,4α)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● I⁻

RN 86718-89-0 HCAPLUS

CN Benzamide, N-[1-[4,4-bis(4-fluorophenyl)butyl]-3-hydroxy-4-piperidiny]-4-nitro-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86718-91-4 HCAPLUS

CN Benzamide, N-[1-[4,4-bis(4-fluorophenyl)butyl]-3-methoxy-4-piperidiny]-4-nitro-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86718-97-0 HCAPLUS

CN Benzamide, N-[1-[4,4-bis(4-fluorophenyl)butyl]-3-hydroxy-4-piperidinyl]-2-chloro-4-nitro-, monohydrochloride, trans- (9CI)
(CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 86718-98-1 HCAPLUS

CN Benzamide, 4-amino-5-cyano-N-[1-[(4-fluorophenyl)methyl]-3-methoxy-4-piperidinyl]-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86718-99-2 HCAPLUS

CN Benzamide, N-[1-[4,4-bis(4-fluorophenyl)butyl]-3-methoxy-4-piperidinyl]-2-chloro-4-nitro-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86719-02-0 HCAPLUS

CN Benzamide, 4-amino-N-[1-[4,4-bis(4-fluorophenyl)butyl]-3-hydroxy-4-piperidinyl]-2-methoxy-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86719-04-2 HCAPLUS

CN Benzamide, 5-chloro-2-methoxy-N-[3-methoxy-1-(phenylmethyl)-4-piperidinyl]-4-(methylamino)-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86719-05-3 HCAPLUS

CN Benzamide, 5-chloro-N-[3-hydroxy-1-(phenylmethyl)-4-piperidinyl]-2-methoxy-4-(methylamino)-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86719-06-4 HCAPLUS

CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[3-methoxy-1-[(3-methoxyphenyl)methyl]-4-piperidinyl]-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86719-07-5 HCAPLUS

CN Benzamide, 4-amino-N-[1-(1,3-benzodioxol-5-ylmethyl)-3-methoxy-4-piperidinyl]-5-chloro-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86719-08-6 HCAPLUS

CN Benzamide, 2-chloro-N-[3-hydroxy-1-(phenylmethyl)-4-piperidinyl]-6-methoxy-4-(methylamino)-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86719-09-7 HCAPLUS

CN Benzamide, 2-chloro-6-methoxy-N-[3-methoxy-1-(phenylmethyl)-4-piperidinyl]-4-(methylamino)-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86719-10-0 HCAPLUS

CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[3-methoxy-1-[(4-methoxyphenyl)methyl]-4-piperidinyl]-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86719-12-2 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[cyclohexylbis(4-fluorophenyl)methyl]-3-methoxy-4-piperidinyl]-2-methoxy-, cis-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86719-13-3 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-(cyclopropylmethyl)-3-methoxy-4-piperidinyl]-2-methoxy-, cis-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86719-14-4 HCAPLUS

CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[3-methoxy-1-(1-methylethyl)-4-piperidinyl]-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86719-18-8 HCAPLUS

CN Benzamide, 4-amino-2-ethoxy-N-[3-hydroxy-1-(phenylmethyl)-4-piperidinyl]-5-nitro-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86719-26-8 HCAPLUS

CN Benzamide, 4-amino-5-cyano-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl]-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86719-27-9 HCAPLUS

CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[3-methoxy-1-[(4,5,6,7-tetrahydro-1H-benzimidazol-2-yl)methyl]-4-piperidinyl]-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86719-29-1 HCAPLUS

CN Benzamide, 4-amino-5-cyano-2-methoxy-N-[3-methoxy-1-(phenylmethyl)-4-piperidinyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 86719-34-8 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[3-[2-(diethylamino)ethoxy]-1-[3-(4-fluorophenoxy)propyl]-4-piperidinyl]-2-methoxy-, dihydrochloride,

cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 86719-36-0 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(acetylamino)-2-methoxy-5-(methylthio)benzoyl]amino]-3-methoxy-, ethyl ester, cis- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 86719-37-1 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[4-cyano-4,4-bis(4-fluorophenyl)butyl]-3-methoxy-4-piperidinyl]-2-methoxy-, cis- (9CI). (CA INDEX NAME)


Relative stereochemistry.



RN 86719-38-2 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[3-[(4-fluorophenyl)sulfonyl]propyl]-3-methoxy-4-piperidinyl]-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86719-39-3 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[3-ethoxy-1-(2-pyridinylmethyl)-4-piperidinyl]-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86719-40-6 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[3-hydroxy-1-(2-pyridinylmethyl)-4-piperidinyl]-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86719-41-7 HCAPLUS

CN 1-Piperidineacetamide, 4-[(4-amino-5-chloro-2-methoxybenzoyl)amino]- α,α -bis(4-fluorophenyl)-3-methoxy-N,N-dimethyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 86719-42-8 HCAPLUS

CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[3-methoxy-1-[(5-methyl-1H-

imidazol-4-yl)methyl]-4-piperidinyl]-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86719-43-9 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[3-[4-fluoro-2-(4-fluorobenzoyl)phenoxy]propyl]-3-methoxy-4-piperidinyl]-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86719-44-0 HCAPLUS

CN Benzamide, 4-amino-N-[1-[3-[2-(aminocarbonyl)-4-fluorophenoxy]propyl]-3-methoxy-4-piperidinyl]-5-chloro-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86719-45-1 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[3-(4-chloro-2-methylphenoxy)propyl]-3-methoxy-4-piperidinyl]-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86719-46-2 HCAPLUS

CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[3-methoxy-1-[3-[3-(trifluoromethyl)phenoxy]propyl]-4-piperidinyl]-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86719-47-3 HCAPLUS

CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[3-methoxy-1-[3-(4-nitrophenoxy)propyl]-4-piperidinyl]-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86719-48-4 HCAPLUS

CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[3-methoxy-1-(3-phenoxypropyl)-4-piperidinyl]-, monohydrochloride, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 86719-49-5 HCAPLUS


CN Benzamide, 4-amino-N-[1-[[2,2-bis(4-fluorophenyl)-1,3-dioxolan-4-yl]methyl]-3-methoxy-4-piperidinyl]-5-chloro-2-methoxy- (9CI) (CA INDEX NAME)



RN 86719-51-9 HCAPLUS

CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[3-methoxy-1-(4-oxo-5,5-diphenylpentyl)-4-piperidinyl]-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 86719-52-0 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[4-(4-fluorophenyl)-3-hydroxy-4,4-dimethoxybutyl]-3-methoxy-4-piperidinyl]-2-methoxy- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 86719-53-1 HCAPLUS


CN Benzamide, 4-amino-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl]-2-methoxy-5-(methylsulfinyl)-, (3 α ,4 α)-(9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 86719-58-6 HCAPLUS


CN 1-Piperidinebutanamide, 4-[(4-amino-5-chloro-2-methoxybenzoyl)amino]-3-hydroxy-N,N,gamma-trimethyl-alpha,alpha-diphenyl- (9CI) (CA INDEX NAME)



RN 86719-59-7 HCAPLUS

CN 1-Piperidinebutanamide, 4-[(4-amino-5-chloro-2-methoxybenzoyl)amino]-3-methoxy-N,N-dimethyl-alpha,alpha-diphenyl-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86719-60-0 HCAPLUS


CN Benzamide, 4-amino-5-chloro-N-[1-[2-[(4-fluorobenzoyl)amino]ethyl]-3-methoxy-4-piperidinyl]-2-methoxy-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 86719-65-5 HCAPLUS


CN Benzamide, 4-amino-N-[1-[4,4-bis(4-fluorophenyl)-2-hydroxybutyl]-3-hydroxy-4-piperidinyll]-5-chloro-2-methoxy- (9CI) (CA INDEX NAME)




RN 86719-66-6 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)-2-hydroxypropyl]-3-methoxy-4-piperidinyll]-2-methoxy- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 86719-67-7 HCAPLUS

CN Benzamide, 4-amino-N-[1-[4,4-bis(4-fluorophenyl)-2-hydroxybutyl]-3-methoxy-4-piperidinyll]-5-chloro-2-methoxy- (9CI) (CA INDEX NAME)




RN 86719-68-8 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[2-(1,4-dihydro-2,4-dioxo-3(2H)-quinazolinyl)ethyl]-3-methoxy-4-piperidinyll]-2-methoxy-, cis-

(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86719-69-9 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[4-(4-fluoro-2-hydroxyphenyl)-4-oxobutyl]-3-methoxy-4-piperidiny]-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86719-70-2 HCAPLUS

CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[3-methoxy-1-(pyrazinylmethyl)-4-piperidiny]-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86719-72-4 HCAPLUS


CN Benzamide, 4-amino-5-chloro-N-(1-ethyl-3-methoxy-4-piperidinyl)-2-hydroxy-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 86719-73-5 HCAPLUS


CN Benzamide, 4-amino-N-[1-[4,4-bis(4-fluorophenyl)-1-methylbutyl]-3-methoxy-4-piperidinyl]-5-chloro-2-methoxy- (9CI) (CA INDEX NAME)



RN 86719-74-6 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-(2,3-dihydro-1H-inden-2-yl)-3-methoxy-4-piperidinyl]-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86719-75-7 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[2-(cyclohexyloxy)ethyl]-3-methoxy-4-piperidinyl]-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86719-76-8 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-(2-furanylmethyl)-3-methoxy-4-piperidinyl]-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86719-83-7 HCAPLUS

CN Benzamide, N-[1-[3-(2-acetylphenoxy)propyl]-3-methoxy-4-piperidinyl]-4-amino-5-chloro-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86719-84-8 HCAPLUS

CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[3-methoxy-1-[3-(2-methoxyphenoxy)propyl]-4-piperidinyl]-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86719-85-9 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[2-(diethylamino)ethyl]-3-methoxy-4-piperidinyl]-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86719-88-2 HCAPLUS

CN 1,3-Benzenedicarboxamide, 4-amino-N1-[1-[3-(4-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl]-6-methoxy-, cis-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86719-89-3 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[5-(4-fluorophenoxy)pentyl]-3-methoxy-4-piperidinyl]-2-methoxy-, cis-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86719-90-6 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[3-(diphenylamino)propyl]-3-methoxy-4-piperidinyl]-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86719-91-7 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[6-(4-fluorophenoxy)hexyl]-3-methoxy-4-piperidinyl]-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86719-92-8 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[3-[(4-fluorophenyl)[(4-methylphenyl)sulfonyl]amino]propyl]-3-methoxy-4-piperidinyl]-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86719-93-9 HCAPLUS

CN Benzamide, 4-amino-N-[1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-3-methoxy-4-piperidinyl]-5-chloro-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86719-94-0 HCAPLUS

CN 1-Piperidinepropanamide, 4-[(4-amino-5-chloro-2-methoxybenzoyl)amino]-3-methoxy-N,N-diphenyl-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86719-95-1 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[3-[(4-fluorobenzoyl)(4-fluorophenyl)amino]propyl]-3-methoxy-4-piperidinyl]-2-methoxy-,
cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 86719-96-2 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)-2-methylpropyl]-3-methoxy-4-piperidinyl]-2-methoxy- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 86719-97-3 HCAPLUS
 CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[3-methoxy-1-(4,4,4-triphenylbutyl)-4-piperidinyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 86719-98-4 HCAPLUS


CN Benzamide, 4-amino-5-chloro-N-[1-[3-[1-(4-fluorophenyl)-1,3-dihydro-1-isobenzofuranyl]propyl]-3-methoxy-4-piperidiny]-2-methoxy- (9CI) (CA INDEX NAME)



RN 86719-99-5 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[3-(cyclohexyloxy)propyl]-3-methoxy-4-piperidiny]-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86720-04-9 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-3-methoxy-4-piperidiny]-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86720-05-0 HCAPLUS

CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[3-methoxy-1-(2-naphthalenylmethyl)-4-piperidinyl]-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86720-06-1 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[2-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)ethyl]-3-methoxy-4-piperidinyl]-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86720-07-2 HCAPLUS

CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[3-methoxy-1-(2-propenyl)-4-piperidinyl]-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86720-08-3 HCAPLUS

CN 1-Piperidineacetamide, 4-[(4-amino-5-chloro-2-methoxybenzoyl)amino]-N-(2,6-dichlorophenyl)-3-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86720-09-4 HCAPLUS

CN 1-Piperidinepropanamide, 4-[(4-amino-5-chloro-2-methoxybenzoyl)amino]-N-(2,6-dichlorophenyl)-3-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86720-10-7 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[3-(5-chloro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-3-methoxy-4-piperidiny]-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86720-11-8 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)butyl]-3-methoxy-4-piperidiny]-2-methoxy-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 86720-12-9 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[3-(3-chlorophenyl)-2-propenyl]-3-methoxy-4-piperidiny]-2-methoxy-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry unknown.



RN 86720-13-0 HCAPLUS

CN 1-Piperidinepropanamide, 4-[(4-amino-5-chloro-2-methoxybenzoyl)amino]-N-(2,6-dimethylphenyl)-3-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86720-14-1 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[2-[(2,6-dichlorobenzoyl)amino]ethyl]-3-methoxy-4-piperidinyl]-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86720-15-2 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-3-hydroxy-4-piperidinyl]-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86720-16-3 HCAPLUS

CN Benzamide, N-[1-[3-(2-acetyl-4-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl]-4-amino-5-chloro-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86720-17-4 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[2-(4-fluorophenoxy)ethyl]-3-methoxy-4-piperidinyl]-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 86720-18-5 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[2-(2,4-dichlorophenoxy)propyl]-3-methoxy-4-piperidinyl]-2-methoxy- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 86720-19-6 HCAPLUS
 CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[3-methoxy-1-(3-pyridinylmethyl)-4-piperidinyl]-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86720-24-3 HCAPLUS

CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[3-methoxy-1-(2-pyridinylmethyl)-4-piperidinyl]-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86720-25-4 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[[5-(4-fluorophenyl)-3-isoxazolyl]methyl]-3-methoxy-4-piperidinyl]-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86720-26-5 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[[4-(1H-imidazol-1-yl)phenyl]methyl]-3-methoxy-4-piperidinyl]-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86720-27-6 HCAPLUS

CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[3-methoxy-1-[[3-(trifluoromethyl)phenyl]methyl]-4-piperidinyl]-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86720-28-7 HCAPLUS

CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[3-methoxy-1-[(2-methylimidazo[1,2-a]pyridin-7-yl)methyl]-4-piperidinyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 86720-29-8 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-(imidazo[1,2-a]pyridin-7-

ylmethyl)-3-methoxy-4-piperidinyl]-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86720-30-1 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[4-(4-fluorophenoxy)butyl]-3-methoxy-4-piperidinyl]-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86720-39-0 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[(4-chlorophenyl)methyl]-3-hydroxy-4-piperidinyl]-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86720-41-4 HCAPLUS

CN Benzamide, 4-amino-N-[1-[4,4-bis(4-chlorophenyl)butyl]-3-hydroxy-4-piperidinyl]-5-chloro-2-methoxy-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 86720-42-5 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[3-hydroxy-1-(3-phenyl-2-propenyl)-4-piperidinyl]-2-methoxy-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry unknown.



RN 86720-43-6 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[3-hydroxy-1-(2-naphthalenylmethyl)-4-piperidinyl]-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86720-45-8 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[3-hydroxy-1-(2-propenyl)-4-piperidinyl]-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86720-47-0 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[(4-fluorophenyl)methyl]-3-methoxy-4-piperidinyl]-2-methoxy-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 86720-48-1 HCAPLUS

CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[3-methoxy-1-(3-phenyl-2-propenyl)-4-piperidinyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry unknown.



RN 86720-49-2 HCAPLUS


CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[3-methoxy-1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 86720-50-5 HCAPLUS


CN Benzamide, 4-amino-5-chloro-N-[1-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-3-methoxy-4-piperidinyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 86720-51-6 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[(4-chlorophenyl)methyl]-3-methoxy-4-piperidinyl]-2-methoxy-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 86720-52-7 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl]-2-methoxy-, cis-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 81098-60-4
CMF C23 H29 Cl F N3 O4

Relative stereochemistry.




CM 2

CRN 144-62-7
CMF C2 H2 O4




RN 86720-53-8 HCAPLUS
CN Benzamide, 4-amino-5-chloro-N-[1-[(3-fluorophenyl)methyl]-3-methoxy-4-piperidinyl]-2-methoxy-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 86720-54-9 HCAPLUS
CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[3-methoxy-1-[[4-(1-methylethyl)phenyl]methyl]-4-piperidinyl]-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86720-55-0 HCAPLUS

CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[3-methoxy-1-[(4-methylphenyl)methyl]-4-piperidiny]-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86720-56-1 HCAPLUS

CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[3-methoxy-1-(4-pyridinylmethyl)-4-piperidiny]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 86720-57-2 HCAPLUS

CN Benzamide, N-[1-[[5-(acetyloxy)-2-furanyl]methyl]-3-methoxy-4-piperidiny]-4-amino-5-chloro-2-methoxy-, cis- (9CI) (CA INDEX NAME)

NAME)


Relative stereochemistry.



RN 86720-58-3 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[2-(4-fluorophenyl)-2-oxoethyl]-3-methoxy-4-piperidinyl]-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86720-59-4 HCAPLUS

CN Benzamide, 4-amino-N-[1-(1H-benzimidazol-2-ylmethyl)-3-methoxy-4-piperidinyl]-5-chloro-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86720-60-7 HCAPLUS

CN Benzamide, 4-amino-N-[1-[[4-(aminosulfonyl)phenyl]methyl]-3-methoxy-4-piperidinyl]-5-chloro-2-methoxy-, monohydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 86720-61-8 HCAPLUS


CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[3-methoxy-1-(2-thienylmethyl)-4-piperidinyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 86720-62-9 HCAPLUS
 CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[3-methoxy-1-[2-(2-methoxyphenoxy)ethyl]-4-piperidinyll]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 86720-63-0 HCAPLUS
 CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[3-methoxy-1-(2-phenoxypropyl)-4-piperidinyll]- (9CI) (CA INDEX NAME)



RN 86720-65-2 HCAPLUS
 CN 1-Piperidinepentanoic acid, 4-[(4-amino-5-chloro-2-methoxybenzoyl)amino]- α,α -bis(4-fluorophenyl)-3-methoxy-, ethyl ester, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86720-66-3 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[3-[(4-fluorophenyl)thio]propyl]-3-methoxy-4-piperidinyl]-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86720-67-4 HCAPLUS

CN 1-Piperidineacetamide, 4-[(4-amino-5-chloro-2-methoxybenzoyl)amino]-N-(2,6-dimethylphenyl)-3-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86720-68-5 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[3-ethoxy-1-[3-(4-fluorophenoxy)propyl]-4-piperidinyl]-2-methoxy-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 86720-69-6 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[4-(4-fluorophenyl)-3-butenyl]-3-methoxy-4-piperidinyl]-2-methoxy-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry unknown.



RN 86720-70-9 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[2-(1H-indol-3-yl)ethyl]-3-methoxy-4-piperidinyl]-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86720-71-0 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[3-(4-fluoro-2-nitrophenoxy)propyl]-3-methoxy-4-piperidinyl]-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86720-72-1 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl]-2-methoxy-N-methyl-, monohydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 86720-73-2 HCAPLUS

CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[3-methoxy-1-[(4-nitrophenyl)methyl]-4-piperidinyl]-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86720-74-3 HCAPLUS

CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[3-methoxy-1-[2-(phenylamino)ethyl]-4-piperidinyl]-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 86720-75-4 HCAPLUS

CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[3-methoxy-1-(2-pyridinylmethyl)-4-piperidinyl]-N-methyl-, dihydrochloride, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● 2 HCl


RN 86720-76-5 HCAPLUS

CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[3-methoxy-1-[1-(2-pyridinyl)ethyl]-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



RN 86720-77-6 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[(4-fluorophenyl)-2-thienylmethyl]-3-methoxy-4-piperidinyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 86729-78-4 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[2-hydroxy-3-[methyl(phenylmethyl)amino]propyl]-3-methoxy-4-piperidinyl]-2-methoxy-, ethanedioate (1:2) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 86729-77-3


CMF C25 H35 Cl N4 O4



CM 2

CRN 144-62-7


CMF C2 H2 O4



RN 86848-63-7 HCAPLUS

CN Benzamide, 4-(acetylamino)-N-[3-(acetyloxy)-1-(2-pyridinylmethyl)-4-piperidinyl]-5-chloro-2-methoxy-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 104466-82-2 HCAPLUS


CN Benzamide, 4-amino-N-[(3R,4S)-1-[4,4-bis(4-fluorophenyl)butyl]-3-methoxy-4-piperidinyl]-2-methoxy-, rel-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 104466-81-1

CMF C30 H35 F2 N3 O3


Relative stereochemistry.



CM 2

CRN 144-62-7


CMF C2 H2 O4



RN 104860-19-7 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-(3-hydroxy-4-piperidiny1)-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 104860-57-3 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[3-hydroxy-1-(phenylmethyl)-4-piperidiny1]-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 104860-58-4 HCAPLUS

CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[3-methoxy-1-(phenylmethyl)-4-piperidiny1]-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 104860-59-5 HCAPLUS

CN Benzamide, 4-amino-N-[1-[4,4-bis(4-fluorophenyl)butyl]-3-hydroxy-4-piperidinyl]-5-chloro-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 104860-60-8 HCAPLUS

CN Benzamide, 4-amino-N-[1-[4,4-bis(4-fluorophenyl)butyl]-3-hydroxy-4-piperidinyl]-5-chloro-2-methoxy-, monohydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 104860-61-9 HCAPLUS

CN Benzamide, 4-amino-N-[1-[4,4-bis(4-fluorophenyl)butyl]-3-methoxy-4-piperidiny]-5-chloro-2-methoxy-, monohydrochloride, cis- (9CI)
(CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 104860-63-1 HCAPLUS


CN Benzamide, 4-amino-N-[1-[4,4-bis(4-fluorophenyl)butyl]-3-methoxy-4-piperidiny]-5-chloro-2-methoxy-, trans-, ethanedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 104860-62-0

CMF C30 H34 Cl F2 N3 O3


Relative stereochemistry.



CM 2

CRN 144-62-7


CMF C2 H2 O4



RN 104860-64-2 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[(3R,4S)-1-[3-(4-fluorophenoxy)propyl]-3-hydroxy-4-piperidinyl]-2-methoxy-, rel-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 104860-66-4 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl]-2-methoxy-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 104860-67-5 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[4-(4-fluorophenyl)-4-oxobutyl]-3-methoxy-4-piperidinyl]-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 104860-68-6 HCAPLUS

CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[3-methoxy-1-(3-methoxypropyl)-4-piperidinyl]-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 104860-69-7 HCAPLUS

CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[3-methoxy-1-(4-oxopentyl)-4-piperidiny]-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 104889-57-8 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(4-amino-5-chloro-2-methoxybenzoyl)amino]-3-hydroxy-, ethyl ester, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 104889-60-3 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[3-hydroxy-1-(phenylmethyl)-4-piperidiny]-2-methoxy-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 104889-62-5 HCAPLUS


CN Benzamide, 4-amino-5-chloro-2-methoxy-N-[3-methoxy-1-(phenylmethyl)-4-piperidiny]-, trans-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 104889-61-4

CMF C21 H26 Cl N3 O3


Relative stereochemistry.



CM 2

CRN 144-62-7


CMF C2 H2 O4



RN 105249-04-5 HCAPLUS

CN Benzamide, 4-amino-5-bromo-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl]-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 105249-07-8 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl]-2-methoxy-, hydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● x HCl

RN 137472-66-3 HCAPLUS

CN Benzamide, 4-(acetylamino)-5-chloro-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl]-2-methoxy-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 182008-76-0 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[2-chloro-4-[[[1-[3-(4-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl]amino]carbonyl]-5-methoxyphenyl]-2-methoxy-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 1-B

—NH₂

IT 86718-43-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and gastric motility activity of)
 RN 86718-43-6 HCAPLUS
 CN Benzamide, 4-amino-5-chloro-N-(3-ethoxy-4-piperidinyl)-2-methoxy-,
 cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IC C07D211-58; C07D401-06; C07D405-06; C07D409-06; C07D413-06;
C07D471-04; C07D407-12; A61K031-00
CC 27-16 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1, 63
IT 869-24-9 1716-42-3 5081-87-8 6959-48-4 15257-81-5
73763-95-8 86721-12-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(alkylation by, of piperidine derivs.)
IT 98-17-9 118-93-4 366-69-8 371-41-5 727-31-1 2559-64-0
83863-69-8 85817-03-4 85817-06-7 86717-95-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(alkylation of)
IT 54-96-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(condensation of, with Me isothiocyanate)
IT 504-63-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(condensation of, with difluoronitrobenzene)
IT 288-32-4, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(condensation of, with fluorobenzoate)
IT 39262-24-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(condensation of, with fluorobenzoylpiperidine)
IT 451-46-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(condensation of, with imidazole)
IT 556-61-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(condensation of, with pyridinediamine)
IT 81098-60-4P 81098-60-4P 83863-69-8P
83863-70-1P 86717-82-0P 86717-86-4P 86717-87-5P
86717-88-6P 86717-89-7P 86718-39-0P 86718-41-4P
86718-44-7P 86718-45-8P 86718-46-9P
86718-47-0P 86718-48-1P 86718-49-2P
86718-50-5P 86718-51-6P 86718-52-7P
86718-54-9P 86718-55-0P 86718-56-1P
86718-57-2P 86718-58-3P 86718-59-4P
86718-60-7P 86718-62-9P 86718-63-0P
86718-64-1P 86718-65-2P 86718-66-3P
86718-69-6P 86718-70-9P 86718-71-0P
86718-72-1P 86718-73-2P 86718-75-4P
86718-76-5P 86718-87-8P 86718-88-9P
86718-89-0P 86718-90-3P 86718-91-4P
86718-92-5P 86718-93-6P 86718-97-0P
86718-98-1P 86718-99-2P 86719-02-0P
86719-03-1P 86719-04-2P 86719-05-3P
86719-06-4P 86719-07-5P 86719-08-6P
86719-09-7P 86719-10-0P 86719-12-2P
86719-13-3P 86719-14-4P 86719-15-5P
86719-16-6P 86719-17-7P 86719-18-8P 86719-21-3P
86719-26-8P 86719-27-9P 86719-29-1P
86719-30-4P 86719-32-6P 86719-34-8P 86719-35-9P
86719-36-0P 86719-37-1P 86719-38-2P
86719-39-3P 86719-40-6P 86719-41-7P
86719-42-8P 86719-43-9P 86719-44-0P
86719-45-1P 86719-46-2P 86719-47-3P
86719-48-4P 86719-49-5P 86719-51-9P
86719-52-0P 86719-53-1P 86719-55-3P
86719-56-4P 86719-57-5P 86719-58-6P
86719-59-7P 86719-60-0P 86719-61-1P

86719-62-2P 86719-64-4P 86719-65-5P
86719-66-6P 86719-67-7P 86719-68-8P
86719-69-9P 86719-70-2P 86719-71-3P
86719-72-4P 86719-73-5P 86719-74-6P
86719-75-7P 86719-76-8P 86719-77-9P
86719-78-0P 86719-79-1P 86719-80-4P 86719-81-5P
86719-82-6P 86719-83-7P 86719-84-8P
86719-85-9P 86719-87-1P 86719-88-2P
86719-89-3P 86719-90-6P 86719-91-7P
86719-92-8P 86719-93-9P 86719-94-0P
86719-95-1P 86719-96-2P 86719-97-3P
86719-98-4P 86719-99-5P 86720-00-5P
86720-01-6P 86720-02-7P 86720-03-8P 86720-04-9P
86720-05-0P 86720-06-1P 86720-07-2P
86720-08-3P 86720-09-4P 86720-10-7P
86720-11-8P 86720-12-9P 86720-13-0P
86720-14-1P 86720-15-2P 86720-16-3P
86720-17-4P 86720-18-5P 86720-19-6P
86720-20-9P 86720-21-0P 86720-22-1P 86720-24-3P
86720-25-4P 86720-26-5P 86720-27-6P
86720-28-7P 86720-29-8P 86720-30-1P
86720-31-2P 86720-32-3P 86720-33-4P 86720-34-5P
86720-35-6P 86720-36-7P 86720-37-8P 86720-38-9P
86720-39-0P 86720-41-4P 86720-42-5P
86720-43-6P 86720-44-7P 86720-45-8P
86720-47-0P 86720-48-1P 86720-49-2P
86720-50-5P 86720-51-6P 86720-52-7P
86720-53-8P 86720-54-9P 86720-55-0P
86720-56-1P 86720-57-2P 86720-58-3P
86720-59-4P 86720-60-7P 86720-61-8P
86720-62-9P 86720-63-0P 86720-65-2P
86720-66-3P 86720-67-4P 86720-68-5P
86720-69-6P 86720-70-9P 86720-71-0P
86720-72-1P 86720-73-2P 86720-74-3P
86720-75-4P 86720-76-5P 86720-77-6P
86729-75-1P 86729-76-2P 86729-78-4P
86848-63-7P 86848-64-8P 86848-65-9P 86848-67-1P
104466-82-2P 104860-19-7P 104860-57-3P
104860-58-4P 104860-59-5P 104860-60-8P
104860-61-9P 104860-63-1P 104860-64-2P
104860-66-4P 104860-67-5P 104860-68-6P
104860-69-7P 104889-57-8P 104889-60-3P
104889-62-5P 105249-04-5P 105249-07-8P
137472-66-3P 182008-76-0P

RL: BAC (Biological activity or effector, except adverse); BSU
(Biological study, unclassified); SPN (Synthetic preparation);
BIOL (Biological study); PREP (Preparation)
(preparation and gastric motility activity of)

IT 86718-43-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and gastric motility activity of)

IT 104860-35-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP
(Preparation); RACT (Reactant or reagent)
(preparation and reductive **condensation** of, with
bis(fluorophenyl)butyraldehyde)

IT 86718-24-3

RL: RCT (Reactant); RACT (Reactant or reagent)
(reductive **condensation** of, with piperidine derivative)

derivatives of 3-amino-3-deoxy-4-thio-DL-threofuranose suitable for synthesis of adriamycin analogs. Jones, John O.; McElhinney, R. Stanley (Lab. Med. Res. Counc. Ireland, Trinity Coll., Dublin, 2, Ire.). Journal of Chemical Research, Synopses (5), 116 (English) 1982. CODEN: JRPSDC. ISSN: 0308-2342.

GI




AB Using standard procedures some derivs. of the title sugar were prepared E.g., the azidothiofuran I (R = β -N₃) was prepared in 4 steps from I (R = α -OH), and underwent reduction, trifluoroacetylation/esterification, and alkoxylation to give thiofuranoses II (R = Ac, CHMe₂, cyclohexyl).

IT 696-07-1

RL: RCT (Reactant); RACT (Reactant or reagent)
(condensation reaction of, with acetoxithiofuranose)

RN 696-07-1 HCAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 5-iodo- (9CI) (CA INDEX NAME)




IT 82480-23-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and acetylation of)

RN 82480-23-7 HCAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[tetrahydro-4-[(4-nitrobenzoyl)oxy]-1-oxido-3-thienyl]-, (1 α ,3 α ,4 β)- (9CI) (CA INDEX NAME)




IT 82480-17-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP
(Preparation); RACT (Reactant or reagent)
(preparation and intramol. cyclization of)

RN 82480-17-9 HCAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[4-(acetyloxy)-5-(3,4-dihydro-5-iodo-
2,4-dioxo-1(2H)-pyrimidinyl)tetrahydro-3-thienyl]-,
(3 α ,4 β ,5 β)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 82480-22-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP
(Preparation); RACT (Reactant or reagent)
(preparation and oxidation of)

RN 82480-22-6 HCAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[tetrahydro-4-[(4-nitrobenzoyl)oxy]-3-
thienyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 82480-18-0P 82480-19-1P 82480-24-8P


82480-25-9P 82480-26-0P 82510-64-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 82480-18-0 HCAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[5-(3,4-dihydro-5-iodo-2,4-dioxo-1(2H)-pyrimidinyl)tetrahydro-4-hydroxy-3-thienyl]-, (3 α ,4 β ,5 β)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 82480-19-1 HCAPLUS

CN 2,5-Methano-5H-pyrimido[1,6-c][1,3,5]thiadiazepine-7,9(1H,8H)-dione, 2,3-dihydro-11-hydroxy-, (2 α ,5 α ,11R*)- (9CI)
(CA INDEX NAME)

RN 82480-24-8 HCAPLUS


CN Acetamide, N-[5-(acetyloxy)tetrahydro-4-[(4-nitrobenzoyl)oxy]-3-thienyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)



RN 82480-25-9 HCAPLUS


CN Acetamide, 2,2,2-trifluoro-N-[tetrahydro-5-(1-methylethoxy)-4-[(4-nitrobenzoyl)oxy]-3-thienyl]-, (3 α ,4 β ,5 α)- (9CI)
(CA INDEX NAME)

Relative stereochemistry.




RN 82480-26-0 HCAPLUS
 CN Acetamide, N-[5-(cyclohexyloxy)tetrahydro-4-[(4-nitrobenzoyl)oxy]-3-thienyl]-2,2,2-trifluoro-, (3 α ,4 β ,5 α)- (9CI)
 (CA INDEX NAME)

Relative stereochemistry.



RN 82510-64-3 HCAPLUS
 CN Acetamide, 2,2,2-trifluoro-N-[tetrahydro-4-[(4-nitrobenzoyl)oxy]-1-oxido-3-thienyl]-, (1 α ,3 β ,4 α)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




CC 33-3 (Carbohydrates)
 IT 696-07-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (condensation reaction of, with acetoxythiofuranose)

- IT 82480-02-2P 82480-14-6P 82480-23-7P 82510-61-0P
82510-63-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); **RACT** (Reactant or reagent) (preparation and acetylation of)
- IT 82480-15-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); **RACT** (Reactant or reagent) (preparation and **condensation** reaction of, with iodouracil)
- IT 82480-17-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); **RACT** (Reactant or reagent) (preparation and intramol. cyclization of)
- IT 82479-99-0P 82480-10-2P 82480-12-4P 82480-22-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); **RACT** (Reactant or reagent) (preparation and oxidation of)
- IT 52693-39-7P 82479-95-6P 82480-01-1P 82480-03-3P
82480-06-6P 82480-09-9P 82480-11-3P 82480-13-5P
82480-16-8P 82480-18-0P 82480-19-1P
82480-24-8P 82480-25-9P 82480-26-0P
82480-27-1P 82510-62-1P 82510-64-3P
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)


L177 ANSWER 9 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN
1981:65461 Document No. 94:65461 4-Unsubstituted azetidinone derivatives. Hashimoto, Masashi; Hemmi, Keiji; Kamiya, Takashi; Komori, Tadaaki; Nakaguti, Osamu; Saito, Yoshihisa; Shiokawa, Youichi; Takasugi, Hisahi; Takaya, Takao; Teraji, Tsutomu (Fujisawa Pharmaceutical Co., Ltd., Japan). U.S. US 4207234 19800610, 130 pp. Cont.-in-part of U.S. Ser. No. 694,891, abandoned. (English). CODEN: USXXAM. APPLICATION: US 1977-858375 19771207.

GI



- AB Lactacillanic acids and analogs I (R = NH₂, acylamino, benzenesulfonamido; R₁ = CO₂H, pharmaceutically acceptable salt or ester derivative of CO₂H; R₂ = H, NH₂, NO₂, halo, alkoxy, alkylthio; R₃ = H, OH, alkyl, alkylthio, OCH₂Ph; R₄ = H, Halo, alkoxy, alkylthio), which showed bactericidal activity, were prepared. Thus, 3-aminolactacillanic acid reacted with PhCH₂COCl in water-Me₂CO containing NaHCO₃ to yield I (R = PhCH₂CONH, R₁ = CO₂H, R₃ = OH, R₂ = R₄ = H).
- IT 59510-73-5
RL: RCT (Reactant); **RACT** (Reactant or reagent) (deacylation of)
- RN 59510-73-5 HCAPLUS

CN 1-Azetidineacetic acid, 3-[[[4-[3-(benzoylamino)-3-carboxypropoxy]phenyl][4-(methoxycarbonyl)-2-nitrophenyl]amino]acetyl]amino]- α -(4-hydroxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)




IT 75269-88-4 75269-90-8 75269-91-9

RL: RCT (Reactant); RACT (Reactant or reagent)
(deprotection of)

RN 75269-88-4 HCAPLUS

CN 1-Azetidineacetic acid, 3-[[[4-chloro-2-[4-[(phenylmethoxy)carbonyl]amino]benzoyl]phenoxy]acetyl]amino]phenylacetyl]amino]- α -(4-hydroxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B


OH

RN 75269-90-8 HCAPLUS


CN 1-Azetidineacetic acid, 3-[[[4-chloro-2-[4-[[[2-

[[(phenylmethoxy) carbonyl] amino] ethyl] thio] acetyl] amino] benzoyl] ph
enoxy] acetyl] amino] phenylacetyl] amino] - α - (4-hydroxyphenyl) -2-
oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 75269-91-9 HCAPLUS

CN 1-Azetidineacetic acid, α - (4-hydroxyphenyl) -2-oxo-3-[[4-
[[(phenylmethoxy) carbonyl] amino] benzoyl] amino] - (9CI) (CA INDEX
NAME)




IT 59509-23-8P 59509-24-9P 59509-25-0P
59509-30-7P 59509-38-5P 59509-39-6P
59509-56-7P 59509-99-8P 59510-56-4P
59510-61-1P 59510-73-5P 59510-74-6P
59511-32-9P 59511-33-0P 59511-34-1P
59511-54-5P 59511-62-5P 59511-79-4P
59511-83-0P 59511-91-0P 64026-69-3P
75261-03-9P 75261-04-0P 75261-10-8P
75269-85-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 59509-23-8 HCAPLUS

CN 1-Azetidineacetic acid, α - (4-hydroxyphenyl) -2-oxo-3-[[4-
[[(phenoxyacetyl) amino] benzoyl] amino] - (9CI) (CA INDEX NAME)




RN 59509-24-9 HCAPLUS

CN 1-Azetidineacetic acid, 3-[(3,5-dinitrobenzoyl)amino]-α-(4-hydroxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)




RN 59509-25-0 HCAPLUS

CN 1-Azetidineacetic acid, α-(4-hydroxyphenyl)-3-[(4-nitrobenzoyl)amino]-2-oxo- (9CI) (CA INDEX NAME)




RN 59509-30-7 HCAPLUS

CN 1-Azetidineacetic acid, α-(3-aminophenyl)-2-oxo-3-[(phenylacetyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 59509-38-5 HCAPLUS

CN 1-Azetidineacetic acid, α-(3-nitrophenyl)-2-oxo-3-[(phenylacetyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 59509-39-6 HCAPLUS

CN 1-Azetidineacetic acid, 2-oxo-3-[(phenylacetyl)amino]-α-[3-
 [[(phenylmethoxy)carbonyl]amino]phenyl]-, methyl ester (9CI) (CA
 INDEX NAME)




RN 59509-56-7 HCAPLUS

CN 1-Azetidineacetic acid, 3-[(4-aminobenzoyl)amino]-α-(4-
 hydroxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)




RN 59509-99-8 HCAPLUS

CN 1-Azetidineacetic acid, α-(4-hydroxyphenyl)-3-[[[(4-
 nitrophenyl)acetyl]amino]-2-oxo- (9CI) (CA INDEX NAME)




RN 59510-56-4 HCAPLUS

CN 1-Azetidineacetic acid, 3-[[[[[4-chloro-2-(4-
 nitrobenzoyl)phenoxy]acetyl]amino]phenylacetyl]amino]-α-(4-
 hydroxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)




RN 59510-61-1 HCAPLUS

CN 1-Azetidineacetic acid, 3-[[[2-[4-[(bromoacetyl)amino]benzoyl]-4-chlorophenoxy]acetyl]amino]phenylacetyl]amino]-α-(4-hydroxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 59510-73-5 HCAPLUS

CN 1-Azetidineacetic acid, 3-[[[4-[3-(benzoylamino)-3-carboxypropoxy]phenyl][4-(methoxycarbonyl)-2-nitrophenyl]amino]acetyl]amino]-α-(4-hydroxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)




RN 59510-74-6 HCAPLUS


CN 1-Azetidineacetic acid, 3-[[[4-[3-carboxy-3-[[4-(methoxycarbonyl)-2-nitrophenyl]amino]acetyl]amino]phenyl][4-(methoxycarbonyl)-2-nitrophenyl]amino]acetyl]amino]-α-(4-hydroxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)

2-nitrophenyl] amino] propoxy] phenyl] [[4-(methoxycarbonyl)-2-nitrophenyl] amino] acetyl] amino] - α -(4-hydroxyphenyl)-2-oxo-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 59511-32-9 HCAPLUS

CN 1-Azetidineacetic acid, 3-[[[[[2-[4-[[[(carboxymethyl)thio]acetyl] amino]benzoyl]-4-chlorophenoxy]acetyl] amino]phenylacetyl] amino]- α -(4-hydroxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 59511-33-0 HCAPLUS
 CN 1-Azetidineacetic acid, 3-[[[[[2-[4-[[[(2-amino-2-carboxyethyl)thio]acetyl]amino]benzoyl]-4-chlorophenoxy]acetyl]amino]phenylacetyl]amino]-α-(4-hydroxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 59511-34-1 HCAPLUS
 CN 1-Azetidineacetic acid, 3-[[[[[2-[4-[[[(2-aminoethyl)thio]acetyl]amino]benzoyl]-4-chlorophenoxy]acetyl]amino]phenylacetyl]amino]-α-(4-hydroxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B




RN 59511-54-5 HCAPLUS
 CN 1-Azetidineacetic acid, 3-[[[[[2-(4-aminobenzoyl)-4-chlorophenoxy]acetyl]amino]phenylacetyl]amino]-α-(4-hydroxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)




RN 59511-62-5 HCAPLUS

CN 1-Azetidineacetic acid, 3-[[[4-[[[3-carboxy-4-hydroxyphenyl]sulfonyl]amino]phenyl]acetyl]amino]-α-(4-hydroxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 59511-79-4 HCAPLUS


CN 1-Azetidineacetic acid, α-[[[4-[3-carboxy-3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propoxy]phenyl][4-(methoxycarbonyl)-2-nitrophenyl]amino]acetyl]amino]-α-(4-hydroxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 59511-83-0 HCAPLUS


CN 1-Azetidineacetic acid, 3-[[[3,5-diaminobenzoyl]amino]-α-(4-hydroxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)

hydroxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)




RN 59511-91-0 HCAPLUS

CN Glycinamide, N-[4-(methoxycarbonyl)-2-nitrophenyl]glycyl-N-[1-carboxy(4-hydroxyphenyl)methyl]-2-oxo-3-azetidinyl]-2-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 64026-69-3 HCAPLUS

CN 1-Azetidineacetic acid, α -(4-hydroxyphenyl)-2-oxo-3-[[[(1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinyl)carbonyl]amino]-, monosodium salt (9CI) (CA INDEX NAME)

● Na

RN 75261-03-9 HCAPLUS


CN 1-Azetidineacetic acid, 3-[[[[[4-chloro-2-[4-[(chloroacetyl)amino]benzoyl]phenoxy]acetyl]amino]phenylacetyl]amino]- α -(4-hydroxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 75261-04-0 HCAPLUS

CN Ethanaminium, 2-[[[4-[2-[2-[[2-[1-[carboxy(4-hydroxyphenyl)methyl]-2-oxo-3-azetidiny]amino]-2-oxo-1-phenylethyl]amino]-2-oxoethoxy]-5-chlorobenzoyl]phenyl]amino]-N,N,N-trimethyl-2-oxo-, chloride (9CI) (CA INDEX NAME)

PAGE 1-A


● Cl⁻

PAGE 1-B

OH


RN 75261-10-8 HCAPLUS

CN 1-Azetidineacetic acid, α-(4-hydroxyphenyl)-2-oxo-3-[[[(1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinyl)carbonyl]amino]-(9CI) (CA INDEX NAME)



RN 75269-85-1 HCAPLUS

CN 1-Azetidineacetic acid, 3-[[[4-chloro-2-[4-[(2-pyridinylthio)acetyl]amino]benzoyl]phenoxy]acetyl]amino]phenylacetyl]amino]-α-(4-hydroxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)




IT 75270-00-7 75270-03-0 75270-09-6

RL: RCT (Reactant); **RACT** (Reactant or reagent)
(saponification of)

RN 75270-00-7 HCAPLUS

CN 1-Azetidineacetic acid, 3-[[[4-[[[4-hydroxy-3-(methoxycarbonyl)phenyl]sulfonyl]amino]phenyl]acetyl]amino]-α-(4-hydroxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)




RN 75270-03-0 HCAPLUS


CN 1-Azetidineacetic acid, 3-[[[4-chloro-2-[4-[[[(2-methoxy-2-oxoethyl)thio]acetyl]amino]benzoyl]phenoxy]acetyl]amino]phenylacetyl]amino]-α-(4-hydroxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)

yl]amino]- α -(4-hydroxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B



RN 75270-09-6 HCAPLUS
 CN 1,2-Benzenedicarboxylic acid, 4-[[[4-[2-[[1-[carboxy(4-hydroxyphenyl)methyl]-2-oxo-3-azetidinyl]amino]-2-oxoethyl]phenyl]amino]sulfonyl]-, 1-methyl ester (9CI) (CA INDEX NAME)




IT 59510-61-1
 RL: PROC (Process)
 (substitution of, with thiols)
 RN 59510-61-1 HCAPLUS
 CN 1-Azetidineacetic acid, 3-[[[2-[4-[(bromoacetyl)amino]benzoyl]-4-chlorophenoxy]acetyl]amino]phenylacetyl]amino]- α -(4-hydroxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)



IT 75261-03-9

RL: RCT (Reactant); RACT (Reactant or reagent)
(substitution reaction of, with pyridinethiol)


RN 75261-03-9 HCAPLUS

CN 1-Azetidineacetic acid, 3-[[[4-chloro-2-[4-
[(chloroacetyl)amino]benzoyl]phenoxy]acetyl]amino]phenylacetyl]ami
no]-α-(4-hydroxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)

IT 75244-54-1 75244-56-3 75244-58-5


RL: RCT (Reactant); RACT (Reactant or reagent)
(N-acylation of)

RN 75244-54-1 HCAPLUS


CN 1-Azetidineacetic acid, 3-amino-α-(3-aminophenyl)-2-oxo-,
methyl ester (9CI) (CA INDEX NAME)

RN 75244-56-3 HCAPLUS


CN 1-Azetidineacetic acid, 3-amino-α-(3-nitrophenyl)-2-oxo-,
methyl ester (9CI) (CA INDEX NAME)




RN 75244-58-5 HCAPLUS
 CN 1-Azetidineacetic acid, 3-amino-2-oxo-α-[3-
 [(phenylmethoxy)carbonyl]amino]phenyl]-, methyl ester (9CI) (CA
 INDEX NAME)




IT 3346-64-3
 RL: RCT (Reactant); **RACT (Reactant or reagent)**
 (N-acylation of aminolactacillanic acid by)
 RN 3346-64-3 HCAPLUS
 CN 4-Pyrimidinecarbonyl chloride, 1,2,3,6-tetrahydro-2,6-dioxo- (9CI)
 (CA INDEX NAME)




IT 75263-49-9 75263-50-2 75263-70-6
 RL: RCT (Reactant); **RACT (Reactant or reagent)**
 (N-alkylation of)
 RN 75263-49-9 HCAPLUS
 CN Benzamide, 3,5-dinitro-N-(2-oxo-3-azetidiny)- (9CI) (CA INDEX
 NAME)




RN 75263-50-2 HCAPLUS
 CN Benzamide, 4-nitro-N-(2-oxo-3-azetidiny)- (9CI) (CA INDEX NAME)



RN 75263-70-6 HCAPLUS
 CN Benzeneacetamide, 4-nitro-N-(2-oxo-3-azetidiny)- (9CI) (CA INDEX NAME)



IT 75270-37-0
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (N-sulfonylation of, by benzenesulfonyl chloride derivative)
 RN 75270-37-0 HCAPLUS
 CN 1-Azetidineacetic acid, 3-[[[(4-aminophenyl)acetyl]amino]-α-(4-hydroxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)



IC C07D205-08; C07D401-12; C07D403-12; C07D409-12
 INCL 260239000A
 CC 27-5 (Heterocyclic Compounds (One Hetero Atom))
 IT 59508-89-3
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (condensation of, with aminooxyacetic acid)
 IT 79-19-6 563-41-7 593-56-6 622-33-3 75261-36-8
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (condensation reaction of, with
 (phenylglyoxyloylamino)lactacillanic acid derivative)
 IT 123-46-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (condensation reaction of, with
 [(formylphenoxy)acetamido]lactacillanic acid derivative)
 IT 59510-69-9 59510-71-3 59510-73-5 59510-75-7
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (deacylation of)
 IT 59509-98-7 59510-42-8 59510-65-5 59510-94-0 59511-72-7
 59511-73-8 59512-00-4 64027-04-9 64027-07-2 64027-12-9
 64027-14-1 64027-32-3 75269-87-3 75269-88-4

75269-89-5 75269-90-8 75269-91-9 75269-92-0

75269-93-1 75269-94-2

RL: RCT (Reactant); RACT (Reactant or reagent)

(deprotection of)

IT	19789-85-6P	30017-02-8P	59508-81-5P	59508-82-6P
	59508-84-8P	59508-85-9P	59508-86-0P	59508-87-1P
	59508-88-2P	59508-89-3P	59508-90-6P	59508-91-7P
	59508-94-0P	59508-96-2P	59508-97-3P	59508-98-4P
	59508-99-5P	59509-00-1P	59509-01-2P	59509-02-3P
	59509-03-4P	59509-04-5P	59509-05-6P	59509-06-7P
	59509-07-8P	59509-08-9P	59509-09-0P	59509-10-3P
	59509-11-4P	59509-12-5P	59509-13-6P	59509-14-7P
	59509-15-8P	59509-16-9P	59509-17-0P	59509-19-2P
	59509-20-5P	59509-21-6P	59509-22-7P	59509-23-8P
	59509-24-9P	59509-25-0P	59509-26-1P	
	59509-27-2P	59509-28-3P	59509-30-7P	59509-31-8P
	59509-32-9P	59509-33-0P	59509-35-2P	59509-36-3P
	59509-37-4P	59509-38-5P	59509-39-6P	
	59509-40-9P	59509-41-0P	59509-42-1P	59509-43-2P
	59509-44-3P	59509-45-4P	59509-46-5P	59509-47-6P
	59509-49-8P	59509-50-1P	59509-51-2P	59509-52-3P
	59509-53-4P	59509-54-5P	59509-55-6P	59509-56-7P
	59509-57-8P	59509-58-9P	59509-59-0P	59509-60-3P
	59509-61-4P	59509-62-5P	59509-63-6P	59509-64-7P
	59509-65-8P	59509-66-9P	59509-67-0P	59509-68-1P
	59509-69-2P	59509-70-5P	59509-72-7P	59509-73-8P
	59509-74-9P	59509-75-0P	59509-76-1P	59509-77-2P
	59509-78-3P	59509-79-4P	59509-80-7P	59509-81-8P
	59509-82-9P	59509-83-0P	59509-84-1P	59509-85-2P
	59509-86-3P	59509-87-4P	59509-89-6P	59509-90-9P
	59509-91-0P	59509-92-1P	59509-93-2P	59509-94-3P
	59509-96-5P	59509-97-6P	59509-98-7P	59509-99-8P
	59510-00-8P	59510-01-9P	59510-02-0P	59510-03-1P
	59510-05-3P	59510-06-4P	59510-07-5P	59510-08-6P
	59510-10-0P	59510-11-1P	59510-12-2P	59510-13-3P
	59510-14-4P	59510-15-5P	59510-16-6P	59510-17-7P
	59510-19-9P	59510-20-2P	59510-21-3P	59510-22-4P
	59510-24-6P	59510-25-7P	59510-26-8P	59510-27-9P
	59510-28-0P	59510-29-1P	59510-30-4P	59510-31-5P
	59510-32-6P	59510-33-7P	59510-36-0P	59510-37-1P
	59510-39-3P	59510-40-6P	59510-41-7P	59510-42-8P
	59510-43-9P	59510-44-0P	59510-45-1P	59510-46-2P
	59510-47-3P	59510-48-4P	59510-49-5P	59510-50-8P
	59510-51-9P	59510-52-0P	59510-53-1P	59510-54-2P
	59510-55-3P	59510-56-4P	59510-57-5P	59510-58-6P
	59510-60-0P	59510-61-1P	59510-62-2P	59510-63-3P
	59510-64-4P	59510-65-5P	59510-66-6P	59510-68-8P
	59510-71-3P	59510-72-4P	59510-73-5P	
	59510-74-6P	59510-75-7P	59510-84-8P	59510-90-6P
	59510-91-7P	59510-96-2P	59511-07-8P	59511-09-0P
	59511-10-3P	59511-11-4P	59511-13-6P	59511-14-7P
	59511-15-8P	59511-16-9P	59511-18-1P	59511-19-2P
	59511-20-5P	59511-21-6P	59511-22-7P	59511-24-9P
	59511-25-0P	59511-26-1P	59511-27-2P	59511-28-3P
	59511-29-4P	59511-30-7P	59511-31-8P	59511-32-9P
	59511-33-0P	59511-34-1P	59511-35-2P	
	59511-36-3P	59511-37-4P	59511-38-5P	59511-39-6P
	59511-40-9P	59511-41-0P	59511-42-1P	59511-45-4P
	59511-46-5P	59511-47-6P	59511-48-7P	59511-49-8P
	59511-50-1P	59511-51-2P	59511-52-3P	59511-53-4P
	59511-54-5P	59511-55-6P	59511-56-7P	59511-57-8P
	59511-58-9P	59511-59-0P	59511-60-3P	59511-61-4P

59511-62-5P 59511-63-6P 59511-64-7P 59511-66-9P
 59511-67-0P 59511-68-1P 59511-70-5P 59511-72-7P
 59511-74-9P 59511-75-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

IT 59511-76-1P 59511-77-2P 59511-78-3P 59511-79-4P
 59511-81-8P 59511-82-9P 59511-83-0P 59511-84-1P
 59511-86-3P 59511-87-4P 59511-89-6P 59511-90-9P
 59511-91-0P 59511-92-1P 59511-93-2P 59511-96-5P
 59511-97-6P 59511-99-8P 59512-01-5P 59512-02-6P
 59512-03-7P 59547-68-1P 59547-69-2P 59547-70-5P
 62105-86-6P 62634-84-8P 64026-60-4P 64026-63-7P
 64026-64-8P 64026-68-2P 64026-69-3P 64026-75-1P
 64026-77-3P 64026-78-4P 64026-79-5P 64026-80-8P
 64026-81-9P 64026-82-0P 64026-84-2P 64026-85-3P
 64026-86-4P 64026-88-6P 64026-89-7P 64026-90-0P
 64026-91-1P 64026-94-4P 64026-95-5P 64026-96-6P
 64026-97-7P 64026-98-8P 64026-99-9P 64027-00-5P
 64027-01-6P 64027-02-7P 64027-03-8P 64027-05-0P
 64027-11-8P 64027-13-0P 64027-15-2P 64027-16-3P
 64027-17-4P 64027-18-5P 64027-20-9P 64027-34-5P
 64027-36-7P 64027-37-8P 64027-38-9P 64027-41-4P
 64027-48-1P 64027-51-6P 64027-54-9P 64027-55-0P
 64027-56-1P 64027-58-3P 64027-59-4P 64027-61-8P
 64027-65-2P 64027-66-3P 64027-67-4P 64027-68-5P
 64027-69-6P 64027-71-0P 64027-72-1P 64027-74-3P
 64027-75-4P 64044-42-4P 64044-43-5P 64044-45-7P
 64055-02-3P 64071-81-4P 64078-77-9P 64317-22-2P
 68749-65-5P 75244-57-4P 75244-67-6P 75244-68-7P
 75244-69-8P 75244-70-1P 75244-71-2P 75244-75-6P
 75244-76-7P 75244-77-8P 75244-78-9P 75244-79-0P
 75244-80-3P 75261-03-9P 75261-04-0P
 75261-05-1P 75261-10-8P 75261-12-0P 75261-18-6P
 75261-19-7P 75261-20-0P 75261-21-1P 75261-22-2P
 75261-34-6P 75261-35-7P 75261-38-0P 75261-39-1P
 75261-40-4P 75261-41-5P 75269-82-8P 75269-83-9P
 75269-85-1P 75270-12-1P 75270-36-9P 75270-43-8P
 75270-44-9P 75270-45-0P 75270-46-1P 75270-47-2P
 75270-48-3P 75270-49-4P 75270-50-7P 75270-56-3P
 75270-57-4P 75283-26-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

IT 59511-81-8 59511-87-4 64027-13-0 64027-40-3 64078-77-9
 75261-32-4 75269-95-3 75269-96-4 75269-97-5 75269-98-6
 75269-99-7 75270-00-7 75270-01-8 75270-02-9
 75270-03-0 75270-04-1 75270-05-2 75270-06-3
 75270-07-4 75270-08-5 75270-09-6 75270-10-9
 75270-11-0

RL: RCT (Reactant); RACT (Reactant or reagent)
 (saponification of)

IT 59510-10-0 59510-61-1

RL: PROC (Process)

(substitution of, with thiols)

IT 75261-03-9

RL: RCT (Reactant); RACT (Reactant or reagent)
 (substitution reaction of, with pyridinethiol)

IT 30017-02-8 59510-68-8 59511-00-1 62634-84-8 64027-20-9
 64027-41-4 64027-42-5 75244-52-9 75244-53-0
 75244-54-1 75244-55-2 75244-56-3
 75244-58-5 75244-59-6 75244-60-9 75244-61-0
 75244-62-1 75244-63-2 75244-64-3 75244-65-4 75244-72-3
 75244-73-4 75244-74-5